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1. INTRODUCTION 37,39,43,44,68 
In any type of tablet system, the important variable is the rate at which the 
active substance goes into solution or dissolves. Superdisintegrants such as 
Crospovidones, Sodium Starch Glycolate, and Croscarmellose Sodium are now 
frequently used in tablet formulations to improve the rate and extent of tablet 
disintegration and thus increase the rate of drug dissolution. The bioavailability of 
drug is dependent on in-vivo disintegration, dissolution, and various physiological 
factors. In recent years, scientists have focused their attention on the formulation of 
quickly disintegrating tablets.  
           Therapeutic effectiveness of a drug depends upon the bioavailability and the 
solubility of the drug molecules. Solubility is one of the important parameter to 
achieve the desired concentration of the drug in systemic circulation for 
pharmacological response to be shown. Currently only 8% of the drugs were having 
high solubility and high permeability. Dissolution of drug from a dosage form 
involves at least two consecutive steps. Liberation of the solute or drug from the 
formulation matrix (disintegration), followed by dissolution of the drug 
(solubilisation of the drug particles) in the liquid medium. The overall rate of 
dissolution depends on the slower of these two steps. The relative difference in rates 
should be carefully considered when designing the dissolution method.  
Despite a rising interest in release drug delivery systems, the most common 
tablets that are intended to be swallowed whole, which disintegrates to release their 
medicaments rapidly in the gastro intestinal tract, still remain the dosage form of 
choice for most of the drugs. A number of studies have been published describing the 
effect of operating conditions on granule quality and the optimization of the process. 
For example, the effects of nine different high speed mixers on the porosity and size 
distribution of granules. There is use of a computer optimization technique based on 
response surface methodology to scale up wet granulation process. The discussion of 
factors critical to obtaining granules with desirable physical properties in granulation 
by high speed mixer is important. Evaluation of the granulation end point from the 
perspective of power consumption change is also useful. Disintegrants vary widely 
and have different mechanisms of action ranging from passive solubilisation to the 
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wicking effect of cross linked polysaccharides and the “explosive” type action of the 
superdisintegrants.  
 
Fig No.1.1: Dissolution Mechanism 
 
Mechanism  56,57 
              The active constituents must be released from the tablet as efficiently as 
possible to allow its rapid action. The mechanism of action had shown in Fig No:  2, 3 
and its action in Table No: 1.The mechanism by which the tablets are broken into 
small pieces and then produces a homogeneous suspension is based on: 
 Capillary action 
 High swellability 
 Heat of wetting  
 Particle – particle repulsive forces 
 Deformation  
 Release of Gases 
 By enzymatic action. 
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Fig No.1.2 : Disintegration of tablet by wicking and swelling 
 
 
 No.1.3 : Disintegration by deformation and repulsion 
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Table No.1.1: Mechanism of action of some Superdisintegrants 
 
 
 
 
 
 
 
 
Method of Addition of Disintegrants 45 
Disintegrants are essentially added to tablet granulation for causing the 
compressed tablet to break or disintegrate when placed in aqueous environment. 
There are three methods of incorporating disintegrating agents into the tablet:  
 Internal Addition (Intragranular) 
 External Addition (Extragranular)  
 Partly Internal and External  
Factors affecting action of Disintegrants  45 
 Percentage of disintegrants present in the tablets.  
 Types of substances present in the tablets.  
 Combination of disintegrants.  
 Presence of surfactants.  
 Hardness of the tablets.  
 Nature of Drug substances.  
 Mixing and Screening 
Besides these factors, one which influences the disintegrant action is its mode 
of incorporation of disintegrants. In general, croscarmellose sodium and sodium 
starch glycolate were found to be less sensitive to the mode of incorporation than 
crospovidone.  
The present invention relates to compressed tablets of some poorly soluble 
antiviral drugs that contain one or more disintegrants that enhance the dissolution rate 
of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of 
absorption of the drug to the body. In addition to the active ingredient, solid dosage 
forms contain a number of additional ingredients referred to as excipients. These 
S.NO. Superdisintegrants  Mechanism of action 
1. Ac-di-sol Swelling 
2. Polyplasdone  XL 
Polyplasdone  XL-10
 
Swells very little, return to 
original size after compression 
but act by capillary action 
3. SSG Swelling 
4. MCC Wicking 
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excipients include among others diluents, binders, lubricants, glidants and 
disintegrants. Diluents are used to impart bulk to the formulation to make a tablet a 
practical size for compression. Examples of diluents are lactose and cellulose. Binders 
are agents used to impart cohesive qualities to the powdered material ensuring the 
tablet will remain intact after compression, as well as improving the free-flowing 
qualities of the powder. Examples of typical binders are lactose, starch and various 
sugars. Lubricants have several functions including preventing the adhesion of the 
tablets to the compression equipment and improving the flow of the granulation prior 
to compression or encapsulation. Lubricants are in most cases hydrophobic materials. 
Excessive use of lubricants can result in a formulation with reduced disintegration 
and/or delayed dissolution of the drug substance. Glidants are substances that improve 
the flow characteristics of the granulation material. Examples of glidants include talc 
and colloidal silicon dioxide.  
Many drugs, both in development and already available in the market, have 
the problem of being only poorly soluble in aqueous media (e.g. Efavirenz). The fact 
that more than 40% of newly discovered drugs have little or no water solubility 
presents a serious challenge to the successful development and commercialization of 
new drugs in the pharmaceutical industry. The present study compared various 
superdisintegrants in terms of physicochemical properties by using antiviral drugs by 
wet granulation method, by improving the dissolution characteristics. Because, all the 
superdisintegrants having different mechanisms by acting (e.g. swelling, wicking 
etc.). 
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2. OBJECTIVE 
The objective of the present investigation was to study, to understand the 
effect of superdisintegrants like crospovidones (Polyplasdone XL, XL-10), 
Croscarmellose Sodium and Sodium Starch Glycolate on the dissolution profiling of 
some poorly soluble anti-viral drugs from their respective tablets. For this study four 
different Superdisintegrants were selected. The two grades of crossprovidone differ 
by particle size. 
 Croscarmellose Sodium  (Ac-di-sol) 
 Sodium Starch Glycolate (SSG) 
 Polyplasdone  XL Crossprovidone (PVPPXL) 
 Polyplasdone  XL-10 Crossprovidone (PVPPXL10) 
For the present study  
 Comparison of Polyplasdone XL and XL-10 crossprovidone with innovator 
product (e.g. SUSTIVA) by using wet granulation method. 
           Model drugs were having various solubility according to British 
Pharmacopoeia were selected. For these study three poorly soluble anti-viral 
drugs were selected and having high market strength. 
 Efavirenz 600mg (SUSTIVA)- Practically insoluble in water 
 Acyclovir 800mg (ZOVIREX)- Slightly soluble in water 
 Nevirapine 200mg (VIRAMUNE)- Sparingly soluble in water 
Rationale for work 
Disintegrants under its consistency of performance are of critical importance 
to the formulation of tablets. In these studies, three antiviral drugs having higher 
marketed dose were selected. The effect of superdisintegrants at 5% use level in the 
tablet formulation on the in vitro dissolution in sink (Compendia or U.S. Food and 
Drug Administration recommended) medium and quasi-sink dissolution medium were 
evaluated. 
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3. PLAN OF STUDY AND STUDY PROTOCOL 
 
3.1. PLAN OF STUDY 
  The present work is to study the effect of four superdisintegrants on three anti- 
viral drugs Efavirenz, Acyclovir and Nevirapine by wet granulation techniques. In the             
present study tablets were prepared at approximately equal hardness. The dissolution 
profiles of drugs were compared for tablets containing different Superdisintegrants, 
then to compare the effect of superdisintegrants effect on the invitro dissolution in 
compendia medium and quasi-sink dissolution medium. Then stability studies for 
three months at three different conditions according to ICH guidelines. 
 
3.2. STUDY PRTOCOL 
Tablets were prepared by wet granulation method. 
Tablets are to be characterized for the following parameters 
¾ Loss on Drying  
¾ Bulk and Tapped Density 
¾ Hardness 
¾ Friability 
¾ Disintegration time 
¾ Assay for granules and tablets 
In-vitro dissolution study by using USP apparatus 2 (Paddle).Determination of DE30 
and T50 and T80.Stability studies for three months at three different conditions 
according to ICH guideline. 
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4. LITERATURE REVIEW 
4.1. REVIEW ON DRUG AND EXCIPIENTS 
Marier J F et al 32 They reported that the efavirenz is a non-nucleoside 
reverse transcriptase inhibitor (NNRTI) that has been used successfully for more than 
a decade to treat Human Immuno Deficiency Virus (HIV) infection. 
Gao J Z et al 15 They reported that the efavirenz is a poorly water soluble and 
highly permeable drug and investigated pharmacoscintigraphic behavior of two 
tablets (efavirenz) and suggested that the difference in in-vivo performance between 
the two tablet and capsule formulations is due to a different rate of in-vivo 
disintegration and suggest that for this drug the in-vivo dissolution and disintegration 
were more important factor affecting the rate and extent of drug absorption. 
Starr S E et al 47 They investigated that the safety, pharmacokinetics, anti 
viral activity and immunologic effects of efavirenz liquid formulation, with nelfinavir 
a nucleoside reverse transcriptase inhibitor (NRTI) in HIV infected children, 3 to 9 
years of age, concluded that combination therapy of liquid formulation with nelfinavir 
is an attractive treatment option for HIV infected children below 3 years of age who 
are unable to take efavirenz capsules.  
Choudhary K P R et al 12,45 They suggested that the poor dissolution 
characteristics of relatively insoluble drugs have long been a problem to the 
pharmaceutical industry. When an insoluble or sparingly soluble drug is administered 
orally, the rate and extent of absorption are controlled by the dissolution rate in the 
gastro intestinal fluids. They suggested the techniques like solid dispersion and use of 
hydrophilic matrix, prodrug approach, complex formation and use of buffering agents, 
surfactants, superdisintegrants to enhance the dissolution and bio-availability of 
poorly soluble drugs.  
Cacace J et al 9 They studied that the comparison of the dissolution of 
Metaxalone Tablets (Skelaxin) Using USP Apparatus 2 and 3. The purpose of this 
study was to evaluate the effect of pH on the dissolution behavior of metaxalone in 
the marketed product Skelaxin tablets. The dissolution was evaluated using United 
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States Pharmacopoeia (USP) dissolution Apparatus 2 and 3 at pHs ranging from 1.5 to 
7.4. Results from these studies show that the dissolution of this product is pH 
dependent. At low pH (simulated gastric fluid, pH 1.5), the dissolution of metaxalone 
from Skelaxin tablets was less than 10% over 75 minutes; whereas, dissolution at pH 
4.5 showed greater than 90% release in the same time period. These results were 
consistent for both Apparatus 2 and 3. This suggests that Skelaxin Tablets should be 
considered a delayed release dosage form.  
Watanable Y et al 52 They reported that the cellulose such as purified 
cellulose, methylcellulose, crosslinked sodium carboxy methylcellulose (Ac-Di-
Sol) and carboxy methyl cellulose are disintegrants to some extent depending on their 
ability to swell on contact with water. A crosslinked form of Ac-Di-Sol has been 
accepted as tablet disintegrant and it is essentially water insoluble. It has high affinity 
for water, which results in rapid tablet disintegration.  
Augsburger et al 5 They  had shown the mechanism of action of 
disintegrants such as Ac-Di-Sol primogel, polyplasdone XL-10 and corn starch 
by rapid liquid absorption and swelling of disintegrant particles which fills 
the void spaces and cause the compact to disintegrate rapidly. Disintegrants, 
however, varied widely in their wicking and swelling properties and minimum 
concentration of disintegrant is necessary to produce primary particles upon 
disintegration and effectively improve drug dissolution. This study was thus 
designed to examine the behavior of disintegrant in their pure state and in 
hard gelatin capsule formulations. The intrinsic ability of disintegrant to 
absorb water and swelling was measured.  
Modi A et al 35 They  investigated enhancement of the dissolution profile of 
valdecoxib using solid dispersion with PVP and also described the preparation of fast 
dissolving tablets of valdecoxib by using a high amount of superdisintegrants. They 
reported the dissolution of valdecoxib improved significantly in solid dispersion 
products.  
Thibert R et al 49 They studied the effects of milling with a ball mill on the 
physical properties and functional behavior of the superdisintegrants SSG (Explotab), 
ac-di-sol, crospovidone. The result showed the milling decrease particle size and 
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increased the surface area of superdisintegrants and no effect on moisture uptake 
behavior.  
Alsaidan S M et al 3 They studied improved dissolution rate of indomethacin 
by adsorbents. Samples of indomethacin and kaolin or microcrystalline cellulose 
(Avicel) were prepared by solvent deposition or simple blending methods. Dissolution 
rates of these samples were studied. The surface adsorption of indomethacin on the 
studied adsorbents was shown to improve the dissolution rate of the drug in water. 
The solvent-deposited samples of indomethacin on kaolin or Avicel in the ratio 1:4 
released 25% of the drug at 34 or 60 min, respectively (t25%), while 25% of the pure 
drug was released at 140 min. Meanwhile, the t25% of the corresponding drug-
adsorbent simple blends was 108 and 110 min, respectively. The effect of addition of 
polyvinyl pyrrolidone (PVP) as a third component to indomethacin-adsorbent was 
studied and showed further improvement in in-vitro availability of the drug-kaolin 
adsorbents.  
Zhao N , Augsburger LL et al 57 They studied that the disintegration 
efficiency, and to develop a discriminating test model for the 3 classes of 
superdisintegrants represented by Ac-Di-Sol, Primojel, and Polyplasdone XL-10. 
Using a digital video camera to examine the disintegration process of tablets 
containing the same wt/wt percentage concentration of the disintegrants, Ac-Di-Sol 
was found to disintegrate tablets rapidly into apparently primary particles; Primojel 
also apparently disintegrated tablets into primary particles but more slowly; 
Polyplasdone XL-10 disintegrated tablets rapidly but into larger masses of aggregated 
particles. The differences in the size distribution generated in the disintegrated tablets 
likely contribute to the drug dissolution rate differences found for aspirin tablets with 
similar disintegration rates. The aspirin tablet matrix is proposed as a model 
formulation for disintegrant efficiency comparison and performance consistency 
testing for quality control purposes.  
Zhao N et al 58 They studied the causes of efficiency loss of 
superdisintegrants following granulation or reworking. Two processes, 
precompression and prewetting, were proposed to simulate the processes during dry 
and wet granulation, respectively. The disintegration efficiency of the resulting 
disintegrant granules was tested in model formulations composed of dicalcium 
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phosphate and lactose with the unprocessed disintegrants as controls. No significant 
difference was shown in the intrinsic swelling and the water uptake abilities of all 
super disintegrants following dry granulation. However, a significant decrease was 
observed for both Primojel and Polyplasdone XL-10 in the rate of water being 
absorbed into the tablet matrix following wet granulation, but not for Ac-Di-Sol. 
United States Pharmacopoeia (USP) disintegration testing without disc revealed a 
significant increase in disintegration time for tablets formulated with dry granulated 
Primojel and Polyplasdone XL-10 and all wet granulated disintegrants. The increase 
in particle size following granulation appears to be the cause of the loss in 
disintegration efficiency. In conclusion, Ac-Di-Sol is less affected by both 
precompression and prewetting. The efficiency of Primojel and Polyplasdone XL-10 
is highly dependent on their particle size. Decreasing the particle size tends to 
increase their efficiency. Due to the size increase following granulation, a higher 
addition level of superdisintegrant is required to ensure fast and uniform 
disintegration of tablets prepared by granulation.  
Souto C et al 46 They studied the utility of including superdisintegrants 
(croscarmellose sodium or sodium starch glycolate) in microcrystalline cellulose 
extrusion-spheronization pellets as a means of increasing the dissolution rate of 
poorly water-soluble drugs. The model drug was hydrochlorothiazide, with water or 
water/ethanol as wetting agent for pellet preparation. Neither disintegrant had 
significant effects on pellet morphology, flow properties or mechanical resistance. 
Nevertheless, the disintegrants afforded a modest increase in drug dissolution rate, 
attributable to the observed increase in pellet micropore volume. Drug dissolution rate 
was slightly higher in pellets prepared with sodium starch glycolate; probably because 
of this disintegrants higher swelling capacity.  
Maria de la Luz Reus Medina et al 31 They studied the evaluation of 
cellulose II powders as a potential multifunctional excipient in tablet formulations. 
They concluded that UICEL-A/102 and UICEL-XL have the potential to be used as 
filler, binder, and disintegrant, all-in-one, in the design of tablets containing either a 
low dose or high dose drug by the direct compression method.  
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            Patel D M et al 38 They prepared the tablet formulation of piroxicam 
containing PVRK 30 and SLS. It showed the formulation increases the dissolution 
profiles.  
Watari Nobutoshi et al 51 They studied the dissolution of Slightly Soluble 
Drugs. II. Effect of Particle Size on Dissolution Behavior in Sodium Lauryl Sulfate 
Solutions. Experiments were made to compare the effect of particle size of 
sulfonamide on the initial dissolution behavior in sodium lauryl sulfate solution and in 
distilled water and the following results were obtained. 1) At agitation speed of 700 
rpm, there was no difference of particle size on the initial dissolution in 0.1% and in 
distilled water but in 1% solution somewhat, and the difference appeared at agitation 
speed of 300 rpm with decrease in particle size. Results obtained in sodium lauryl 
sulfate solution showed a similar tendency while the instantly dissolving part 
increased with decrease in particle size, and this part dissolved instantly at first and 
the constant rate of dissolution followed in distilled water. 2) Plots of log dissolution 
rate constants vs. log agitation speed became linear with the same slope irrespective 
of particle size, when 0.1% and 1% solutions were used. Rank order for the 
dissolution rates of different particle size of powders was possible even at a relatively 
low agitation speed of 200 rpm.  
Mukesh C Gohel et al 36 They studied that the improvement of nimesulide 
dissolution from solid dispersions containing croscarmellose sodium and Aerosil 200 
was found to be >200. They concluded that the Aerosil  effective in increasing the 
drug dissolution compared to croscarmellose sodium.  
Yen S Y et al 55  They studied the dissolution enhancement of nifedepine but 
the solvent deposition techniques on superdisintegrants including ac-di-sol, Kollidon 
CL, SSG, it showed significantly enhanced the rate of dissolution of nifedipine.  
            Jayesh Parmar & Manish Rane 69 They gave information about the oral 
dosage form because, the process of manufacturing tablets is complex. Hence, careful 
consideration payed  to select right process,and right excipients to ultimately give a 
robust, high productivity and regulatory compliant product of good quality. 
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4.2. API SPECIFICATIONS 
4.2.1. EFAVIRENZ 15,32,47,67 
Efavirenz is a human immunodeficiency virus type 1 (HIV-1) specific, non-
nucleoside, reverse transcriptase inhibitor (NNRTI). 
Capsules  
Efavirenz is available as capsules for oral administration containing either 50 mg, 100 
mg, or 200 mg of efavirenz 
Tablets 
Efavirenz is available as film-coated tablets for oral administration containing 600 mg 
of efavirenz.  
Brand name: EFA, STOCRIN, SUSTIVA.  
 
Chemical Name 
8-chloro-5-(2-cyclopropylethynyl)-5-(trifluoromethyl)-4-oxa-2-azabicyclo[4.4.0] 
deca-7,9,11-trien-3-one. 
Empirical Formula C14H9ClF3NO2  
Molecular Weight 315.68   
Melting Point  139-141 °C 
Structural Formula  
 
Solubility   
Practically insoluble in water (<10 mg/mL). 
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Mechanism of Action 
 
Efavirenz falls in the non-nucleoside reverse transcriptase inhibitor (NNRTI) 
class of antiretroviral. Both nucleoside and non-nucleoside RTIs inhibit the same 
target, the reverse transcriptase enzyme, an essential viral enzyme which transcribes 
viral RNA into DNA. Unlike nucleoside RTIs, which bind at the enzyme's active site, 
NNRTIs bind within a pocket termed the NNRTI pocket. 
 
Pharmacokinetics  
The pharmacokinetics of efavirenz have not been studied in patients with renal 
insufficiency; however, less than 1% of efavirenz is excreted unchanged in the urine, 
so the impact of renal impairment on efavirenz elimination should be minimal. A 
multiple-dose study showed no significant effect on efavirenz pharmacokinetics in 
patients with mild hepatic impairment (Child-Pugh Class A) compared with controls. 
There were insufficient data to determine whether moderate or severe hepatic 
impairment (Child-Pugh Class B or C) affects efavirenz pharmacokinetics 
Absorption 
Peak efavirenz plasma concentrations of 1.6-9.1 mM were attained by 5 hours 
following single oral doses of 100 mg to 1600 mg administered to uninfected 
volunteers. Dose-related increases in Cmax and AUC were seen for doses up to 1600 
mg; the increases were less than proportional suggesting diminished absorption at 
higher doses.  
Distribution 
Efavirenz is highly bound (approximately 99.5-99.75%) to human plasma 
proteins, predominantly albumin. In HIV-1 infected patients (n=9) who received 
efavirenz 200 to 600 mg once daily for at least one month, cerebrospinal fluid 
concentrations ranged from 0.26 to 1.19% (mean 0.69%) of the corresponding plasma 
concentration. This proportion is approximately 3-fold higher than the non-protein-
bound (free) fraction of efavirenz in plasma. 
 
                                                                                  LITERATURE REVIEW 
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 15 
 
Metabolism 
Studies in humans and in vitro studies using human liver microsomes have 
demonstrated that efavirenz is principally metabolized by the cytochrome P450 
system to hydroxylated metabolites with subsequent glucuronidation of these 
hydroxylated metabolites. These metabolites are essentially inactive against HIV-1. 
The in-vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes 
responsible for efavirenz metabolism.  
Elimination 
  Efavirenz has a terminal half-life of 52-76 hours after single doses and 40-55 
hours after multiple doses. A one-month mass balance/excretion study was conducted 
using 400 mg per day with a 14C-labeled dose administered on Day 8. Approximately 
14-34% of the radiolabel was recovered in the urine and 16-61% was recovered in the 
feces. Nearly all of the urinary excretion of the radio labeled drug was in the form of 
metabolites. Efavirenz accounted for the majority of the total radioactivity measured 
in feces. 
Drug Interactions 
Efavirenz has been shown in-vivo to cause hepatic enzyme induction, thus increasing 
the biotransformation of some drugs metabolized by CYP3A4. 
Indications 
Efavirenz in combination with other antiretroviral agents is indicated for the treatment 
of HIV-1 infection. This indication is based on two clinical trials of at least one year 
duration that demonstrated prolonged suppression of HIV- RNA. 
Dosage and administration 
The recommended dosage of efavirenz is 600 mg orally, once daily, in 
combination with a protease inhibitor and/or nucleoside analogue reverse 
transcriptase inhibitors (NRTIs). It is recommended that efavirenz be taken on an 
empty stomach, preferably at bedtime. The increased efavirenz concentrations 
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observed following administration of efavirenz with food may lead to an increase in 
frequency of adverse events  
Side effects 
The most significant adverse events observed in patients treated with efavirenz are 
nervous system symptoms, psychiatric symptoms, and rash.  
Contraindications    
Efavirenz is contraindicated in patients with clinically significant hypersensitivity to 
any of its components. Efavirenz should not be administered concurrently with 
artemizole, voriconazole, cisapride, midazolam, triazolam, or ergot derivatives.  
4.2.2. ACYCLOVIR 
Acyclovir is a synthetic nucleoside analogue active against herpes viruses. 
Capsules  
Acyclovir is available as capsules for oral administration containing 200 mg of 
acyclovir. 
Tablets 
Acyclovir is available as for oral administration containing 800 mg and 400mg of 
acyclovir.  
Suspension 
Each teaspoonful (5 mL) of acyclovir Suspension contains 200 mg of acyclovir. 
Brand name  ZOVIRAX  
Chemical Name 
2-amino-1, 9-dihydro-9-[(2-hydroxyethoxy) methyl]-6H-purin-6-one 
Empirical Formula C8H11N5O3  
Molecular Weight 225.205 g/mol  
Melting Point  256.5 - 257 °C  
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Structural Formula 
 
Solubility   
The maximum solubility in water at 37° C is 2.5 mg/mL. 
 
Mechanism of Action 
              
Acyclovir is a synthetic purine nucleoside analogue with in-vitro and in-vivo 
inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and 
varicella-zoster virus (VZV).  
Pharmacokinetics 
The pharmacokinetics of acyclovir after oral administration have been 
evaluated in healthy volunteers and in immunocompromised patients with herpes 
simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are 
summarized in Table No.4.1. 
Table No: 4.1  Acyclovir Pharmacokinetic Characteristics (Range) 
Parameter Range 
Plasma protein binding 9% to 33% 
Plasma elimination half-life 2.5 to 3.3 hr 
Average oral bioavailability 10% to 20%*
 
*Bioavailability decreases with increasing dose. 
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Drug Interactions 
Coadministration of probenecid with intravenous acyclovir has been shown to 
increase the mean acyclovir half-life and the area under the concentration-time curve. 
Urinary excretion and renal clearance were correspondingly reduced. 
Indications 
Herpes Zoster Infections, Genital Herpes, Chickenpox.  
Side effects 
Anaphylaxis, angioedema, fever, headache, pain, peripheral edema.   
Contraindications 
Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or 
valacyclovir.  
4.2.3. NEVIRAPINE 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor with activity against 
Human Immunodeficiency Virus Type 1 (HIV-1).  
Tablets 
Nevirapine is tablets for oral administration containing 200 mg of nevirapine.  
Suspensions 
Each 5 mL of Nevirapine suspension contains 50 mg of nevirapine (as nevirapine 
hemihydrates).  
Brand name  VIRAMUNE 
Chemical Name 
11-cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido [3,2-b:2', 3'-e][1,4] diazepin-6-
one 
Empirical Formula C15H14N4O 
Molecular Weight 266.298 g/mol   
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Melting Point  196.06 
Structural Formula 
 
 
Solubility:   
Sparingly soluble in water (0.7046 mg/L) 
Mechanism of Action 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of 
HIV-1. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-
dependent and DNA-dependent DNA polymerase activities by causing a disruption of 
the enzyme's catalytic site. 
Pharmacokinetics  
  Nevirapine is extensively metabolized in the liver by cytochrome P450 (CYP) 
isoenzymes 3A4 and 2B6, and is mainly excreted into the urine as glucuronidated and 
hydroxylated metabolites (80%) and as parent drug (5%).Nevirapine causes induction 
of its metabolism, resulting in a 1.5- to 2-fold increase in the oral clearance during the 
first weeks of dosing. The plasma elimination half-life is about 45 h after a single 
dose, and about 25-30 h during steady-state dosing.The licensed dosage for nevirapine 
is 200 mg twice-daily, after a starting dose of 200 mg once-daily during the first 2 
weeks of  therapy.   
 
Absorption and Bioavailability 
Nevirapine is readily absorbed (> 90%) after oral administration in healthy 
volunteers and in adults with HIV-1 infection. Absolute bioavailability in 12 healthy 
adults following single-dose administration was 93 ± 9% (mean ± SD) for a 50 mg 
tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 
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0.4 µg/mL (7.5 µM) were attained by 4 hours following a single 200 mg dose. 
Following multiple doses, nevirapine peak concentrations appear to increase linearly 
in the dose range of 200 to 400 mg/day. Steady state trough nevirapine concentrations 
of 4.5 ± 1.9 µg/mL (17 ± 7 µM), (n = 242) were attained at 400 mg/day 
Distribution 
Nevirapine is highly lipophilic and is essentially nonionized at physiologic 
pH. Following intravenous administration to healthy adults, the apparent volume of 
distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is 
widely distributed in humans. Nevirapine readily crosses the placenta and is also 
found in breast milk. 
 Metabolism/Elimination 
 In vivo studies in humans and in vitro studies with human liver microsomes have 
shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) 
metabolism to several hydroxylated metabolites.  
Drug Interactions 
Nevirapine is principally metabolized by the liver via the cytochrome P450 
isoenzymes, 3A4 and 2B6. Nevirapine is known to be an inducer of these enzymes. 
As a result, drugs that are metabolized by these enzyme systems may have lower than 
expected plasma levels when coadministered with nevirapine. These potential drug 
interactions are listed in Table No 3.2. 
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Table No.4.2 Established Drug Interactions: Alteration in Dose or Regimen May 
Be Recommended Based on Drug Interaction Studies 
Drug Name 
Effect on Concentration 
of Nevirapine or 
Concomitant Drug 
Clinical Comment 
Clarithromycin Clarithromycin  14OH- clarithromycin 
Clarithromycin exposure was 
significantly decreased by 
nevirapine; however, 14-OH 
metabolite concentrations were 
increased. 
Ethinyl estradiol and 
Norethindrone 
Ethinyl estradiol 
Norethindrone 
Oral contraceptives and other 
hormonal methods of birth 
control should not be used as the 
sole method of contraception in 
women taking nevirapine, 
Fluconazole  Nevirapine Because of the risk of increased exposure to nevirapine. 
Indinavir Indinavir An increase in the dosage of indinavir may be required. 
Ketoconazole Ketoconazole 
Decreases in ketoconazole 
plasma concentrations may 
reduce the efficacy of the drug. 
Lopinavir/Ritonavir Lopinavir 
A dose increase of 
lopinavir/ritonavir to 533/133 mg 
twice daily with food is 
recommended. 
Methadone Methadone 
Methadone levels may be 
decreased; increased dosages 
may be required to prevent 
symptoms of opiate withdrawal. 
Rifabutin Rifabutin 
Rifabutin and its metabolite 
concentrations were moderately 
increased. 
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Rifampin Nevirapine 
Nevirapine and rifampin should 
not administered concomitantly 
because decreases in nevirapine 
plasma concentrations may 
reduce the efficacy of the drug 
 
Side effects 
The most serious adverse reactions associated with nevirapine are hepatitis/hepatic 
failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity 
reactions.  
Contraindications 
Nevirapine is contraindicated in patients with clinically significant hypersensitivity to 
any of the components contained in the tablet or the oral suspension. 
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4.3. EXCIPIENTS SPECIFICATIONS 2 
4.3.1. CROSCARMELLOSE SODIUM 
Product Description 63.67 
Ac-Di-Sol is FMC Biopolymer’s trademark for an internally cross-linked form 
of sodium carboxymethylcellulose (NaCMC). Ac-Di-Sol differs from soluble sodium 
carboxymethylcellulose only in that it has been cross-linked to ensure that the product 
is essentially water insoluble. It is an odorless, relatively free flowing, white powder. 
Description 
Croscarmellose sodium occurs as odorless, white-colored powder. 
Nonproprietary Names 
USPNF: Croscarmellose sodium 
Synonyms 
Ac-Di-Sol; Crosslinked carboxymethylcellulose sodium; modified cellulose gum; 
Nymcel ZSX; Primellose; Solutab 
Chemical name  
Cellulose, Carboxy methyl ether, sodium salt cross linked  
Empirical formula and Molecular weight: 
Croscarmellose is a cross linked of Carboxy methyl sodium 
Applications in Pharmaceutical Formulation or Technology 
Croscarmellose sodium is used in oral pharmaceutical formulation as a disintegrant 
for tablets, capsules and granules.  
Stability and Storage conditions 
 Sodium is a stable though hygroscopic material. Croscarmellose sodium should be 
stored in a well closed container in a cool, dry place. 
Incompatibility          
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly reduced 
in tablet formulations prepared by wet granulation or direct compression processes 
which contain hygroscopic excipients such as sorbitol. 
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4.3.2. POLYPLASDONE 62 
  Polyplasdone is a synthetic, insoluble, but rapidly swellable, crosslinked 
homopolymer of N-vinyl-2-pyrrolidone.Polyplasdone polymers are synthesized by a 
unique one step polymerization  process known as “popcorn” polymerization where 
the cross linking agent is generated in situ and is, thus chemically similar to the bulk 
of the polymer. This unique manufacturing process results in a densely cross linked 
polymer with porous particle morphology. This distinctive morphology rapidly wicks 
liquids in to the particle to speed swelling and enhance disintegration and dissolution 
of tablets. The particle morphology of Polyplasdone polymers also provides for a 
highly compressible powder with good flow properties that result in hard, non friable 
tablets. 
In addition to its unique particle morphology, Polyplasdone polymers are non 
ionic and, as a result, their disintegration performance will not be impacted by pH 
changes in the gastrointestinal tract nor they will complex with ionic drug actives 
Polyplasdone polymers will not retard the disintegration and dissolution processes 
since they do not form gels. Consequently, Polyplasdone polymers are well suited for 
use as superdisintegrants in a wide range of oral solid dosage formulation. In addition 
to their use as a disintegrant, Polyplasdone polymers can also be used as adsorptive 
polymers, suspension stabilizers, and for bioavailability enhancement in a variety of 
pharmaceutical applications. 
Polyplasdone crospovidone (NF) products are superdisintegrants with the 
greatest rate of swelling of any excipient. They are effective in wet granulation, dry 
granulation and direct compression tablet processing. They are manufactured by a 
unique process. Unlike most polymeric disintegrants which consist of a natural or 
semi natural water soluble polymer which is then cross linked chemically, the 
polymerization and cross-linking occurs simultaneously to yield a controlled insoluble 
mass. This results in amorphous spherical particles which are then spray dried to 
produce free flowing compressible powder to enable even distribution and excellent 
powder flow. The spherical particles unique to Polyplasdone crospovidone 
superdisintegrants distribute evenly throughout the tablet and have a greater surface 
area/volume ratio than other disintegrants. This feature, coupled with the amorphous 
open structure of the particles, result in rapid swelling in all directions in the presence 
of any physiological fluid. This leads to the rapid development of high internal 
stresses which cause the tablet to disintegrate. 
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The fully cross-linked nature of polyplasdone crospovidone means that it is 
completely insoluble and will not develop any viscosity. This precludes the possibility 
of delayed disintegration or even sustained release. It also ensures that its full 
disintegration potential is maintained even after undergoing several wetting/drying 
cycles. 
This mechanism of disintegration is so efficient it renders Polyplasdone XL 
and Polyplasdone XL-10 effective at concentration levels of typically, 1-
3%.Polyplasdone crospovidone can be incorporated at any stage in the pre-tableting 
process to give required control over the rate of disintegration of both tablet and its 
component granules. This means one particle size can be used pre-granulation and a 
different particle size disintegrant post granulation. The smaller particle size product, 
Polyplasdone XL-10 can be used intragranularly (before granulation) to maximize 
distribution, while the larger particle size product, Polyplasdone XL, with its stronger 
disintegration power, is more effective extragranularly. The formulation flexibility 
and excellent functionality of Polyplasdone crospovidone make it a superdisintegrant 
of choice. 
Product Range: 
ISP offers 3 chemically identical Polyplasdone grades differentiated by particle size. 
Polyplasdone XL polymer has the largest average particle size (100-130µ) and 
provides faster disintegration. 
Polyplasdone XL 10 has finer average particle sizes (30-50µ) which enhance content 
uniformity in the formulation of tablets (less than 300mg) and in intragranular 
applications while still providing rapid disintegration. 
Polyplasdone INF -10 polymers has the finest average particle size (5-10µ) of the 
Polyplasdone grades and is highly adsorptive material. 
 
Product profile 
Solubility and Viscosity 
¾ Polyplasdone crospovidone is completely insoluble in water and all solvents as 
a consequence of its cross-linked structure. 
¾ It swells extremely rapidly in water which makes it the premier 
superdisintegrants for solid dosage form. 
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¾ It is hydrophilic and on contact, rapidly absorbs water. This causes massive 
build up of hydrostatic pressure which is a key contributor to its disintegration 
potential 
¾ .It rapidly disperses in water and does not even gel even after prolonged 
exposure. 
¾ It does not affect the viscosity of water or solvents 
 
Particle characteristics 
Polyplasdone crospovidone grades are flowable white powders which are easy 
to handle on a manufacturing scale. Polyplasdone particles are granular and porous. 
This unique particle structure allows for improved flow and quick wicking of liquid in 
to the particle and tablet by capillary action. In addition, this particle morphology 
contributes to the high compressibility of Polyplasone XL and XL-10 polymers. 
Although Polyplasdone XL-10 polymer has smaller particles than Polyplasdone XL 
polymer, the small particles retain their porosity and resulting physical properties. 
 
4.3. Particle characteristics 
 
PRODUCT PARTICLE SIZE(µM) 
TAP 
DENSITY(G/CM³)
BULK 
DENSITY(G/CM³) 
CARR 
INDEX 
(%) 
Polyplasdone 
XL 100 0.3 0.2 22 
Polyplasdone 
XL 10 30 0.5 0.3 30 
Polyplasdone 
INF-10 11 0.5 0.4 20 
 
Flow 
As Polyplasdone polymers are supplied as free-flowing, white powders, they 
are easy to handle during direct compression and wet and dry granulation 
manufacturing processes. Polyplasdone XL and XL-10 polymers have good flow 
properties which are attributed to their granule particle morphology. 
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Table No: 4.4 Flow Characteristics 
 
PROPERTY POLYPLASDONE 
INF-10 XL-10 XL 
Angle of repose(degrees) 41 30 35 
Flowability Index 45 50 47 
 
Compressibility 
Due to their unique particle morphology, Polyplasdone XL and XL-10 
disintegrants are significantly more compressible than other superdisintegrants, 
resulting in harder, less friable tablets. Polyplasdone XL and XL-10 polymers provide 
significantly higher hardness of pure compacts. Consequently, Polyplasdone 
disintegrant is ideally suited for use with poorly compressible actives and in direct 
compression tablet processes. 
 
Adsorption and complexation 
Polyplasdone crospovidone has a high adsorptive capacity and, as well as 
swelling, complexes with many molecules including some drugs and toxins. This is a 
reversible physical complexation without formation of covalent chemical bonds. 
 
Swelling and Hydration 
Although Polyplasdone XL and XL-10 polymers swell by 95-120%, upon 
contact with water, swelling is not thought to be their primary mechanism for 
disintegration. Swelling or swell volume is mainly a measure of the change in the 
volume of the disintegrant after it is introduced to an aqueous solution and system has 
reached equilibrium. Polyplasdone polymers with their porous particle morphology 
rapidly absorb water (wicking) to generate the rapid volume expansion and 
hydrostatic pressure that cause tablet disintegration. Unlike other superdisintegrants 
which rely principally on swelling for disintegration, Polyplasdone disintegrants use 
the combination of swelling and wicking to provide rapid disintegration. 
Also, unlike other common superdisintegrants, the swell volume of 
Polyplasdone polymers is relatively unaffected by changes in pH. As a result of high 
cross link density, Polyplasdone disintegrants swell without gelling. Other 
superdisintegrants have a lower crosslink density and, as a result, forms gels when 
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fully hydrated. Gels can delay dissolution as the drug must first diffuse through the 
gel layer before being released into the body. Also, because Polyplasdone 
disintegrants don’t gel upon wetting, they will maintain their full disintegration 
efficacy even after undergoing several wetting and drying cycles. Therefore, 
polyplasdone disintegrants are ideally suited for use in wet granulation processes. 
 
Applications in pharmaceutical formulations or Technology:  
Polyplasdone crospovidone is used in a range of pharmaceutical applications. 
Polyplasone XL and XL-10 polymers provide rapid disintegration in a wide range of 
oral solid dosage formulations and processes.  
4.3.3. SODIUM STARCH GLYCOLATE 67 
 Nonproprietary Names 
• BP: Sodium starch glycollate 
• PhEur: Carboxymethylamylum natricum 
• USPNF: Sodium starch glycolate 
Synonyms 
Carboxymethyl starch, Sodium salt; Explosol, Explotab, Glycolys, Primojel, Starch 
Carboxymethyl ether, Sodium salt, Tablo, Vivastar P. 
 Chemical Name :    Sodium carboxymethyl starch  
Empirical Formula and Molecular Weight 
Sodium starch glycolate is the sodium salt of a carboxymethyl ether of starch, 
containing 2.8–4.2% sodium.  
Sodium starch glycolate may be characterized by the degree of substitution and 
crosslinking. The molecular weight is typically 5 × 105–1 × 106. 
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Structural Formula 
 
Functional Category 
Tablet and capsule disintegrant. 
Applications in Pharmaceutical Formulation or Technology 
Sodium starch glycolate is widely used in oral pharmaceuticals as a 
disintegrant in capsule and tablet formulations. Disintegration occurs by rapid uptake 
of water followed by rapid and enormous swelling.  
Description 
Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing 
powder.  
Stability and Storage Conditions 
Tablets prepared with sodium starch glycolate have good storage properties. Sodium 
starch glycolate is stable and should be stored in a well-closed container in order to 
protect it from wide variations of humidity and temperature, which may cause caking. 
The physical properties of sodium starch glycolate remain unchanged for up to 3–5 
years if it is stored at moderate temperatures and humidity. 
Incompatibilities 
Sodium starch glycolate is incompatible with ascorbic acid. 
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                            4.4. DISSOLUTION PROFILE COMPARISON 
 In the development of oral controlled release preparations, an ethical or 
proprietary product, which has been available in the market and established its 
efficacy clinically, is usually selected as reference. The generic preparation is always 
formulated with its dissolution profile as closely similar as possible to that of 
proprietary product. Several methods have been proposed to compare the dissolution 
profiles of test with that of reference. Those methods were classified into several 
categories, such as: 
¾ Model Dependent Kinetics 
¾ Model Independent Kinetics 
¾ Statistical methods 
 
Model Dependent Methods 
The model dependent methods all rely upon a curve fitting procedure. 
Different mathematical functions have been used to model the observed data (Costa 
and Sousa Lobo 2001). Both the linear and non-linear models are being used in 
practice for dissolution modeling. Linear models include Zero order, Higuchi, 
Hixson-Crowell, quadratics and polynomials, whereas the nonlinear models include 
First order, Weibull, KorsMeyer-Peppas etc 
 
Model Independent Methods 
Model independent methods were now gaining more popularity in 
pharmaceutical industries to have to compare the dissolution profiles of test and 
reference, which is required at time of submission to US FDA for approval of generic 
drugs. Model independent methods to compare the dissolution profiles are again 
differentiated into ratio tests and pair wise procedures. The ratio tests are relations 
between parameters obtained from the release assay of the reference formulations and 
test product at the same time. To compare dissolution profiles ratio tests like 
Dissolution efficiency (DE), Mean dissolution time (MDT), Time taken to release x% 
drug (tx %). 
 
 
 
 
                                                                                  LITERATURE REVIEW 
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 31 
 
Dissolution Efficiency 
The dissolution efficiency (DE) of a pharmaceutical dosage form is defined as 
the area under dissolution curve up to a certain time, t, expressed as percentage of the 
area of the rectangle described by 100% dissolution in the same time. 
 
 
Mean Dissolution Time 
The mean Dissolution Time is defined as the time required by the dosage form to 
dissolve the 50% of the drug.  
 
Time taken to release x% drug: 
The tx % parameter corresponds to the time necessary to the release of a 
determined percentage of drug (e.g., t 20%,  t 50%, t 80%) and sampling time 
corresponds to the amount of drug dissolved in that time (e.g., t 20,  t 50, t 80). 
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5. EXPERIMENT 
5.1. Instruments 
Table No: 5.1 List of Instruments 
Instrument Source 
 
Granulator 
 
Moisture content 
 
Compression of tablet 
 
 
Hardness Tester 
 
Friabilator 
 
Disintegration Apparatus 
 
UV-Spectrophotometer 
 
Dissolution Apparatus 
 
Sonicator 
 
Electronic balance 
 
pH Meter 
 
Stability Chamber 
 
Bectochem 
 
Sartorius Moisture Balance 
 
CADMACH Square model single sided 
Rotary tablet press CMD4 , Ahmedabad 
 
Erweka TBH 310 MD, Germany 
 
Erweka, Germany 
 
Erweka, Germany 
 
8453 Agilent Technologies, Germany 
 
VK 7010 Varian 
 
Cole Parmer 8890 
 
Sartorius 
 
744 Metrohm 
 
Pooja Labs 
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5.2. Formulation and Development 
General Formula 
Table No: 5.2 The general formula of Efavirenz (600mg) tablets prepared were 
as follows 
S.NO. Ingredients Control Quantity in mg/tablet 
1. Efavirenz 600 600 
2. MCC pH 101 254 204 
3. Lactose Monohydrate 250 240 
4. Sodium Lauryl Sulphate 36 36 
5. Plasdone K29/32 36 36 
6. Superdisintegrants - 60 
7. Magnesium Stearate 12 12 
8. Aerosil 12 12 
Total 1200 1200 
Table No: 5.3 The general formula of Acyclovir (800mg) tablets prepared were 
as follows 
S.NO. Ingredients Control Quantity in mg/tablet 
1. Acyclovir 800 800 
2. MCC pH 101 640 565 
5. Plasdone K29/32 45 45 
6. Superdisintegrants - 75 
7. Magnesium Stearate 10 10 
8. Aerosil 5 5 
Total 1500 1500 
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Table No: 5.4  The general formula of Nevirapine (200mg) tablets prepared were 
as follows 
S.NO. Ingredients Control Quantity in mg/tablet 
1. Nevirapine 200 200 
2. MCC pH 101 305 265 
3. Lactose Monohydrate 302.5 300 
5. Plasdone K29/32 25.5 25.5 
6. Superdisintegrants - 42.5 
7. Magnesium Stearate 8.5 8.5 
8. Aerosil 8.5 8.5 
Total 850 850 
 
Codes 
Efavirenz                               EF 
Acyclovir                              AC 
Nevirapine                             NE 
Crosscarmellose Sodium          T1 
Sodium Starch Glycolate         T2 
Polyplasdone XL                    T3 
Polyplasdone XL10                T4 
 
 
 
Table No: 5.5  Batch Codes 
S.NO. Superdisintegrants Efavirenz 600mg 
Acyclovir 
800mg 
Nevirapine 
200mg 
1. Crosscarmellose Sodium EFT1 ACT1 NET1 
2. Sodium Starch Glycolate EFT2 ACT2 NET2 
3. Polyplasdone XL EFT3 ACT3 NET3 
4. Polyplasdone XL10 EFT4 ACT4 NET4 
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5.3. Compression Technique 
Efavirenz (600mg) 
The required quantities of the ingredients (Efavirenz, MCC pH 101, Lactose 
Monohydrate, Plasdone K29/32, and SLS) were weighed and blended to form a 
homogenous powder by sieve number 30. Then the prepared blends were granulated 
by using procept granulator with water. The wet granules were dried in air drying. 
After drying it was sieved under sieve number 24. The lubricants were sieved under 
sieve number 30 and mixed well. The granules were compressed on 19mm and 9mm 
capsule shaped punch set on Rotary Compression Machine (CAD MACH) at 1200mg 
theoretically weighed and at approximately equal hardness. The compression and 
ejection force simultaneously recorded by AIM software. 
Acyclovir (800mg) 
The required quantities of the ingredients (Acyclovir, MCC pH 101) were 
weighed and blended to form a homogenous powder by sieve number 30. Plasdone 
K29/32 was dissolved in water at 10% w/v. Then the prepared blends were granulated 
by using procept granulator with polyplasdone K29/32 solution. The wet granules 
were dried in air drying. After drying it was sieved under sieve number 24. The 
lubricants were sieved under sieve number 30 and mixed well. The granules were 
compressed on 19mm and 9mm capsule shaped punch set on Rotary Compression 
Machine (CAD MACH) at 1500mg theoretically weighed and at approximately equal 
hardness. The compression and ejection force simultaneously recorded by AIM 
software. 
Nevirapine (200mg) 
The required quantities of the ingredients (Nevirapine, MCC pH 101, Lactose 
Monohydrate) were weighed and blended to form a homogenous powder by sieve 
number 30. Plasdone K29/32 was dissolved in water at 10% w/v. Then the prepared 
blends were granulated by using procept granulator with polyplasdone K29/32 
solution. The wet granules were dried in air drying. After drying it was sieved under 
sieve number 24. The lubricants were sieved under sieve number 30 and mixed well. 
The granules were compressed on 19mm and 9mm  capsule shaped punch set on 
Rotary Compression Machine (CAD MACH) at 1500mg theoretically weighed and at 
approximately equal hardness. The compression and ejection force simultaneously 
recorded by AIM software. 
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Preparation of Granules Using Procept High Shear Granulator 
 The mixing vessel of granulator was charged with drug mixture and pre 
mixed at an impeller speed of 1000rpm for 60sec.Water was added at a pre-
determined rate and after 120sec chopper was started at 2500rpm and granulation 
performed. The impeller torque and product temperature are monitored to determine 
the end point of granulation. Granules sieved through 30 meshes and dried to a final 
moisture content of 1.5-2%w/w (determined using sartorius moisture balance). 
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5.4. Evaluation Techniques 
Evaluation of Granules 
A. Bulk Density, Tapped Density and Compressibility 
Bulk density was measured by tapping method.         
                                              Mass of the sample 
Bulk Density = 
                               Volume of the measuring cylinder   
An automated tap density tester (Procept Density apparatus) was used for 
tapping the powders according to USP Method. In brief, the graduated cylinder was 
mounted on the tap density tester. The powders were filled into the cylinder using a 
funnel, and the volume and weight were recorded to calculate the bulk density. The 
apparatus was tapped for 100 times. The volume was recorded, and the tapped density 
was calculated.  
                                                        Mass of the sample 
Tapped Density = 
                                   Volume of the measuring cylinder after tapping 
Compressibility (%) =(p t a p − p b u l) / p t a p × 100 
where p t a p is the tapped bulk density and p b u l is the initial bulk density.    
 
B. Drug Content Uniformity of Granules 
For Efavirenz 
Accurately weighed granules of equivalent to 600mg of drug were taken in a 
500ml volumetric flask. Then 20 to 30ml of methanol was added to dissolved, and 
then made the volume by using 2% SLS medium. It was filtered. From that 1ml was 
taken in a 100ml volumetric flask and made the volume by using 2% SLS medium 
(12µg/ml). Then the drug content was analyzed by using UV Visible 
Spectrophotometer (Agilent UV-Spectrophotometer at 247 nm and compared with the 
standard. Accurately weighed 600mg pure drug efavirenz was taken in the similar 
manner. The percentage of drug present in the granules was calculated by the 
following equation 
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                                                            Observed drug content                
   The percentage of drug content =                                                    × 100                                             
                                                          Theoretical drug content 
                                                       
For Acyclovir 
The above same method was followed and the granules weight was 800mg 
equivalent was taken. Media was 0.1N HCl and measured at 251nm (16µg/ml). 
For Nevirapine 
Accurately weighed granules of equivalent to 200mg of granules were taken in a 
200ml volumetric flask. Then 20 to 30ml of dimethyl sulphoxide (DMSO) was added to 
dissolved, and then made the volume by using pH 2 Phosphate buffer medium. It was 
filtered. From that 2ml was taken in a 100ml volumetric flask and made the volume by 
using pH 2 Phosphate buffer medium (20µg/ml). Then the drug content was analyzed by 
using UV Visible Spectrophotometer (Agilent UV-Spectrophotometer at 314 nm and 
compared with the standard. Accurately weighed 200mg pure drug nevirapine was taken 
in the similar manner. The percentage of drug present in the granules was calculated by 
the above same method. 
C. Moisture determination for granules: 
The granulation moisture content was determined using Sartorius moisture 
balance. An amount of 1 g of wet granules were exposed for 3 min in quick drying 
mode at 105ºC and percentage of moisture was noted for each case. 
Evaluation of Tablets 
A. Weight variation test 
To study weight variation, 20 tablets of each formulation were weighed using an 
electronic balance (Sartorius), and test was performed according to the official 
method. 
B. Hardness  
For each formulation, the hardness of 10 tablets was determined using Erweka 
hardness tester and average is calculated and presented with standard deviation  
C. Friability 
A sample of 20 tablets was taken and was carefully dedusted prior to testing. 
The tablets were accurately weighed and placed in drum of the Roche Friabilator 
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(Erweka, Germany), and the drum was rotated for 4min at 25rpm, and tablets were 
removed, dedusted and accurately weighed. 
Friability of tablets is calculated by using the following relationship 
                                     %F= W0-Wf /W0 ×100 
Where W0 is the initial weight of 20 tablets and Wf is the final weight of 20 tablets. 
D. Disintegration test 
Disintegration testing was performed at 37ºC in Millipore water using Erweka 
apparatus (Germany) with disks. The test was carried out as per USP and averages of 
6 readings were recorded for each formulation. 
E. Drug content uniformity of tablets 
For Efavirenz 
20 tablets were weighed and made powder by crushing the tablets, from that 
weighed equivalent to 600mg of the drug placed in 500ml beaker. Then 20 to 30ml of 
methanol added to dissolve the drug then made the volume by using medium 2% SLS. 
It was filtered. From that 1ml was taken in a 100ml volumetric flask and made the 
volume by using 2% SLS medium (12µg/ml).  After graded dilution the drug solution 
was analyzed in spectrophotometer (Agilent UV-Spectrophotometer) at 247nm then 
compared to standard. The percentage of drug present in the tablets were calculated 
by the following equation 
                                                         Observed drug content  
The percentage of drug content =                                                 × 100 
                                                          Theoretical drug content 
The above same method was followed and the tablet crushed weight was 800mg 
equivalent was taken. Media was 0.1N HCl and measured at 251nm (16µg/ml). 
For Nevirapine 
20 tablets were weighed and made powder by crushing the tablets, from that 
weighed equivalent to 600mg of the drug placed in 200ml beaker. Then 20 to 30ml of 
dimethyl sulphoxide (DMSO) added to dissolve the drug then made the volume by using 
pH 2 Phosphate buffer medium. It was filtered. From that 2ml was taken in a 100ml 
volumetric flask and made the volume by using pH 2 Phosphate buffer medium 
(20µg/ml).  After graded dilution the drug solution was analyzed in spectrophotometer 
(Agilent UV-Spectrophotometer) at 314nm then compared to standard. The percentage of 
drug present in the granules was calculated by the above same method. 
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F. Moisture determination for tablets: 
One compressed tablet was crushed in a mortar and pestle. The granulation 
moisture content was determined using Sartorius moisture balance. An amount of 1 g 
of granules were exposed for 3 min in quick drying mode at 105ºC and percentage of 
moisture was noted for each case. 
 
G. Analytical Methods 
For Efavirenz 
Preparation of 2% SLS in water 
100 grams of SLS was dissolved in 5 liters of Millipore water and made the 
volume to 5 liters. 
Preparation of Standard Calibration Curve in 2% SLS in water 
              Accurately weighed 100 mg of pure drug were transferred to 250 ml 
volumetric flask and were dissolved in methanol with sonication. The volume was 
made up to 250 ml by using medium (2% SLS in water). From this withdraw 1ml, 
2ml, 3ml, 4ml and 5ml placed in 100ml flask and then made up to 100ml with same 
medium from this graded dilution in the concentration range of 4.0 to 20.0 µg/ml 
were prepared. Before going for spectroscopic analysis drug solution was scanned for 
λmax.  The λmax was found to be 247 nm in buffer. Then absorbance of prepared 
standard solution was measured and plotted against concentration.  Regression 
analysis has been done and standard curve was plotted to get correlation factor = 
0.999. 
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Fig No: 5.1 Graph of Standard Calibration Curve in 2% SLS in water 
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Table No:  5.6  Data of Standard Calibration Curve in 2% SLS in water 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation of 0.2% SLS in water 
10 grams of SLS were dissolved in 5 liters of Millipore water and made the 
volume to 5 liters. 
Preparation of Standard Calibration Curve in 0.2% SLS in water 
Accurately weighed 100 mg of pure drug were transferred to 250 ml 
volumetric flask and were dissolved in methanol with sonication. The volume was 
made up to 250ml  by using medium (0.2% SLS in water). From this withdraw 1ml, 
2ml, 3ml, 4ml, 5ml and 10ml placed in 100ml flask and then made up to 100ml with 
same medium from this graded dilution in the concentration range of 4.0 to 30.0 
µg/ml were prepared. Before going for spectroscopic analysis drug solution was 
scanned for λmax.  The λmax was found to be 247 nm in buffer. Then absorbance of 
prepared standard solution was measured and plotted against concentration.  
Regression analysis has been done and standard curve was plotted to get correlation 
factor = 0.999.  
 
 
 
 
 
 
 
 
 
S.NO. CONCENTRATION IN mcg/ml ABSORBANCE 
1. 4.0 0.18727 
2. 8.0 0.37974 
3. 12.0 0.57549 
4. 16.0 0.75876 
5. 20.0 0.93951 
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Fig No: 5.2  Graph of Standard Calibration Curve in 0.2% SLS in water 
 
Table No: 5.7  Data of Standard Calibration Curve in 0.2% SLS in water 
 
 
Dissolution Parameters 
The tablets were subjected to in-vitro dissolution profiling using Varian 
dissolution apparatus. The dissolution profiles of the Efavirenz-600mg tablets were 
determined using the paddle method (Varian) set with a paddle speed of 50 rpm. 
Dissolution was als       5to tested in two media i.e. 1000ml water with 2% SLS 
(compendia media, USP), 1000ml Water with 0.2% SLS (quasi-sink media). A 
peristaltic pump was coupled to an Auto sampler to provide a continuous flow of drug 
solution through the test tubes. Samples were withdrawn at 5, 10, 15, 30, 45 and 60 
minutes interval, diluted suitably and analyzed for drug content using UV-Visible 
spectrophotometer (Agilent Technologies) at λmax = 247 nm. The data given were the 
mean of 6 determinations. 
For Acyclovir 
Preparation of 0.1N HCl 
170ml of Concentrated Hydrochloric acid was taken in a beaker containing 3 liters of 
water and made the volume up to 20 liters.  
Preparation of Standard Calibration Curve for 0.1N HCl 
S.NO. CONCENTRATION  IN mcg/ml ABSORBANCE 
1. 4.0 0.16644 
2. 8.0 0.32759 
3. 12.0 0.50564 
4. 16.0 0.68544 
5. 20.0 0.87136 
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Accurately weighed 100 mg of pure drug were transferred to 250 ml 
volumetric flask and were dissolved in methanol with sonication. The volume was 
made up to 250 ml by using medium (0.1N HCl). From this withdraw 1ml, 2ml, 3ml, 
4ml and 5ml placed in 100ml volumetric flask and then made up to 100ml with same 
medium from this graded dilution in the concentration range of 4.0 to 20.0 µg/ml 
were prepared. Before going for spectroscopic analysis drug solution was scanned for 
λmax.  The λmax was found to be 251 nm in buffer. Then absorbance of prepared 
standard solution was measured and plotted against concentration.  Regression 
analysis has been done and standard curve was plotted to get correlation factor = 
0.999.  
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Fig No: 5.3  Graph of Standard Calibration Curve for 0.1N HCl 
 
Table No: 5.8  Data of Standard Calibration Curve for 0.1N HCl 
 
 
 
 
 
 
 
 
 
 
 
S.NO. CONCENTRATION IN mcg/ml ABSORBANCE 
1. 4.0 0.20160 
2. 8.0 0.41606 
3. 12.0 0.63375 
4. 16.0 0.84775 
5. 20.0 1.07800 
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Dissolution Parameters 
The tablets were subjected to in-vitro dissolution profiling using Varian 
dissolution apparatus. The dissolution profiles of the Acyclovir-800mg tablets were 
determined using the paddle method (Varian) set with a paddle speed of 50 rpm. 
Dissolution was also tested in two media i.e. 900ml 0.1N HCl(compendia media, 
USP), 500ml 0.1N HCl (quasi-sink media). A peristaltic pump was coupled to an 
Auto sampler to provide a continuous flow of drug solution through the test tubes. 
Samples were withdrawn at 5, 10, 15, 30, 45 and 60 minutes interval, diluted suitably 
and analyzed for drug content using UV-Visible spectrophotometer (Agilent 
Technologies) at λmax = 251 nm. The data given were the mean of 6 determinations. 
For Nevirapine 
Preparation of 0.1M pH 2 Phosphate Buffer 
3.9ml concentrated phosphoric acid and 5.73G of monobasic sodium 
phosphate monohydrate to a 1 liter volumetric flask, dissolve and dilute with water to 
volume, adjust pH 2.0 ± 0.02.  
 
Preparation of Standard Calibration Curve for 0.1M pH 2 Phosphate Buffer 
Accurately weighed 100 mg of pure drug were transferred to 250 ml 
volumetric flask and were dissolved in dimethyl sulphoxide (DMSO) with sonication. 
The volume was made up to 250 ml by using medium 0.1M pH 2 Phosphate Buffer. 
From this withdraw 1ml, 2ml, 3ml, 4ml and 5ml placed in 100ml volumetric flask and 
then made up to 100ml with same medium from this graded dilution in the 
concentration range of 4.0 to 20.0 µg/ml were prepared. Before going for 
spectroscopic analysis drug solution was scanned for λmax.  The λmax was found to 
be 314 nm in buffer. Then absorbance of prepared standard solution was measured 
and plotted against concentration.  Regression analysis has been done and standard 
curve was plotted to get correlation factor = 0.999. 
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Fig No: 5.4 Graph of Standard Calibration Curve for 0.1M pH 2 Phosphate 
Buffer 
 
Table No: 5.9  Data of Standard Calibration Curve for 0.1M pH 2 Phosphate 
Buffer 
 
 
Dissolution Parameters 
The tablets were subjected to in-vitro dissolution profiling using Varian 
dissolution apparatus. The dissolution profiles of the Nevirapine-200mg tablets were 
determined using the paddle method (Varian) set with a paddle speed of 50 rpm. 
Dissolution was also tested in two media i.e. 900ml 0.1M pH 2 Phosphate Buffer 
(compendia media, USP), 500ml 0.1M pH 2 Phosphate Buffer (quasi-sink media). A 
peristaltic pump was coupled to an Auto sampler to provide a continuous flow of drug 
solution through the test tubes. Samples were withdrawn at 5, 10, 15, 30, 45 and 60 
minutes interval, diluted suitably and analyzed for drug content using UV-Visible 
spectrophotometer (Agilent Technologies) at λmax = 314 nm. The data given were the 
mean of 6 determinations. 
S.NO. CONCENTRATION IN mcg/ml ABSORBANCE 
1. 4.0 0.10283 
2. 8.0 0.22654 
3. 12.0 0.32451 
4. 16.0 0.44268 
5. 20.0 0.54277 
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Stability Studies 
 The prepared tablets were placed in plastic screw guage containers and stored 
at a different temperature conditions, 25ºC/60%RH, 30ºC/65%RH and 40ºC/75%RH 
according to ICH Guidelines, for a period of three months. The tablets were examined 
for their physical parameters and dissolution comparison at regular intervals of 
30days, 60days and 90days. 
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6. RESULTS AND DISCUSSIONS 
The present study is to understand the effect of superdisintegrants in tablet 
formulations of three poorly soluble anti-viral drugs. According to these study 
Polyplasdone XL-10 crospovidone displayed obvious differences in three various 
parameters.  
 
Physical Parameters 
In physical parameters, all the trials passes the test and within the limits of 
Pharmacopoeia. The physical parameters data were showed in Table No: 6.1 to 6.7, 
6.8 to 6.14 and 6.15 to 6.21. 
In the Disintegration time for Efavirenz, Polyplasdone XL-10 crospovidone is 
equal with innovator disintegrant croscarmelose sodium (Ac-di-sol), (Ac-di-sol) 
showed 5 mins 50 secs, whereas Polyplasdone XL-10 crospovidone was showed 7 
mins 50 secs. 
In acyclovir, Polyplasdone XL crospovidone was first disintegrated at 3 mins 
28 secs, next is Polyplasdone XL-10 crospovidone at 5 mins 24 secs. 
In nevirapine, Polyplasdone XL-10 crospovidone was first disintegrated at 
within 9 secs compared with other superdintegrants used in this study. 
The Particle Size distribution of excipients is of considerable importance when 
formulating tablets. Polyplasdone XL-10 crospovidone has a finer Particle Size 
distribution which improves mixing and minimizes changes in swelling properties and 
on the tablet surface resulting from atmospheric humidity. The above features 
Polyplasdone XL-10 crospovidone has recommended as a high performance 
disintegrant in tablet formulation. 
 
In vitro Drug Release Study 
The release data for all the batches of three antiviral drugs are presented in Fig 
No:6.1, 6.2, 6.3, 6.4, 6.5 and 6.6. 
For Efavirenz 
In both the media (Compendia medium and Quasi-sink medium) Polyplasdone 
XL-10 crospovidone showed faster release than Polyplasdone XL10 crospovidone 
and Croscarmellose Sodium. According to T50 and T80 data showed in Table No: 6.22 
and Fig No: 6.7, 6.8, Polyplasdone XL-10 crospovidone showed faster release 
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compared to other superdisintegrants used in this study. However, in the Quasi-sink 
medium (Compromised Sink Condition) none of the disintegrants achieved 80% 
release. But the tablets with Polyplasdone XL-10 crospovidone showed almost 70% 
release, which was significantly higher than any of the other disintegrants used. 
For Acyclovir 
 In the compendia medium, Polyplasdone XL-10 crospovidone and Sodium 
Starch Glycolate (SSG) were comparable and showed faster release than 
Polyplasdone XL10 crospovidone and croscarmellose Sodium. According to T50 and 
T80 data showed in Table No: 6.23 and Fig No: 6.9, 6.10. However, the Quasi-sink 
was able to discriminate between the different disintegrants, and tablets containing 
Polyplasdone XL-10 crospovidone showed significantly faster release than any of the 
disintegrants. 
For Nevirapine 
 According to T50 and T80 data showed in Table No: 6.24 and Fig No: 6.11, 
6.12, Polyplasdone XL-10 crospovidone, showed faster release compared to other 
disintegrants used in this study in both the Compendia medium and Quasi-sink 
medium. However, in both the medium Polyplasdone XL-10 crospovidone showed 
faster release than other disintegrants used in this study. However this was more 
significantly apparent in the Quasi-sink medium. 
 Polyplasdone XL-10 crospovidone is a synthetic insoluble, but rapidly 
swellable, cross-linked polymer. This distinctive morphology rapidly wicks into the 
particle to speed swelling and enhance disintegration and dissolution of tablets. The 
particle morphology it provides for a highly compressible powder with good flow 
properties that result in hard, non friable tablets. In addition, Polyplasdone XL-10 
crospovidone are non-ionic, they do not form gels, will not retard the disintegration 
and dissolution processes. 
 T50 and T80 values was selected because of according to U.S. Pharmacopoeia, 
and showed a significant difference in to the formulations. 
 Quasi-sink medium was selected for the dissolution studies, because can not 
discriminate between the release rates in the Sink conditions. The release rate equal to 
that 80% was selected, from that in which medium giving 80% release for that drug is 
selected for Quasi-sink i.e. Compromised Sink Condition. From this Polyplasdone 
XL-10 crospovidone showed to discriminate between the different disintegrants used 
in this study. 
                                                                       RESULTS AND DISCUSSION                     
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 49                            
 
 
Dissolution Efficiency 
 In DE30 were showed for all the batches of the model drugs in Fig No: 6.13, 
6.14, 6.15. Compared with other disintegrants Polyplasdone XL-10 crospovidone was 
showed major difference in the DE30. Especially in the model drugs- Acyclovir and 
Nevirapine, Polyplasdone XL-10 crospovidone were having high DE30. 
 
Stability Studies 
 Stability studies for all the batches of the model drugs for three different 
temperature and humidity conditions for the period of three months, there was no 
significant difference in the physical parameters and in vitro dissolution studies 
showed in Table No: 6.25, 6.26, 6.27  and Fig No: 6.16 to 6.18, 6.19 to 6.21, 6.22 to 
6.24, 6.25 to 6.27, 6.28 to 6.30 and 6.31 to 6.33.  
 During Storage at a fairly high relative humidity, tablets can be softer and their 
tensile strength was reduced. Polyplasdone XL and XL-10 crospovidone are insoluble 
in water due to its cross-linked structures and hygroscopic nature; the final finished 
products must be protected from atmosphere humidity having excellent stability with 
no changes in the important product parameters. From that it is concluded that the 
developed formulations were stable in that stability conditions according to ICH 
Guidelines. 
For Efavirenz (600mg) 
 
 
Table No: 6.1 Physical Parameters 
 
Physical 
Parameters 
Batches 
Control EFT1 EFT2 EFT3 EFT4 
Appearance White, capsule Shaped 
LOD for granules %L 1.65 1.52 1.62 1.72 1.68 
Bulk Density (wt/ml) 0.5612 0.5536 0.5542 0.5567 0.5540 
Tapped Density (wt/ml) 0.6254 0.6290 0.6180 0.6322 0.6285 
% Compressibility 10.27 11.99 10.32 11.94 11.85 
Assay 1of granules (%) 99.89 101.06 101.02 99.18 100.12 
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Table No: 6.2 Weight Variation (gm) 
 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4 
1st NA 1.2174± 0.014 
1.2071± 
0.004 
1.208± 
0.003 
1.2101
± 
0.003 
1.2069
± 
0.0018 
30  25ºC/60%RH 1.2071± 0.003 
1.2058± 
0.004 
1.2041
± 
0.003 
1.2072
± 
0.004 
1.2063
± 
0.002 
30  30ºC/65%RH 1.2172± 0.002 
1.2025± 
0.001 
1.2024
± 
0.008 
1.2069
± 
0.002 
1.2051
± 
0.002 
30  40ºC/75%RH 1.2102± 0.003 
1.2055± 
0.004 
1.2063
± 
0.003 
1.2063
± 
0.003 
1.2049
± 
0.003 
60  25ºC/60%RH 1.2094± 0.02 
1.2046± 
0.003 
1.207± 
0.002 
1.2067
± 
0.001 
1.2047
± 
0.001 
60  30ºC/65%RH 1.2082± 0.12 
1.2059± 
0.002 
1.2054
± 
0.001 
1.2051
± 
0.003 
1.2056
± 
0.002 
60  40ºC/75%RH 1.2094± 0.14 
1.2065± 
0.003 
1.2021
± 
0.0006 
1.2047
± 
0.005 
1.2049
± 
0.003 
90  25ºC/60%RH 1.2086± 0.26 
1.2061± 
0.002 
1.2065
± 
0.002 
1.2058
± 
0.001 
1.2065
± 
0.001 
90  30ºC/65%RH 1.2072± 0.32 
1.2063± 
0.002 
1.2064
± 
0.002 
1.2070
± 
0.002 
1.2067
± 
0.002 
90  40ºC/75%RH 1.2064± 0.01 
1.2076± 
0.001 
1.2062
± 
0.002 
1.2061
± 
0.002 
1.2057
± 
0.002 
  n=20, Mean ± S 
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Table No: 6.3  Hardness (N) 
n=10, Mean ± S.D 
 
 
Table No: 6.4  Friability (%) 
 
 
 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4 
1st NA 113±0.35 143± 0.25 
131± 
0.58 
122± 
0.25 
131± 
0.58 
30  25ºC/60%RH 115±0.38 114± 0.37 
119± 
0.2 
113± 
0.25 
124± 
0.37 
30  30ºC/65%RH 125±0.42 113± 0.25 
122± 
0.2 
114± 
0.2 
118± 
0.25 
30  40ºC/75%RH 148±0.37 113± 0.4 
116± 
0.37 
116± 
0.2 
114± 
0.37 
60  25ºC/60%RH 126±0.26 120± 0.55 
120± 
0.32 
116± 
0.37 
122± 
0.25 
60  30ºC/65%RH 131±0.34 115± 0.32 
124± 
0.37 
121± 
0.58 
121± 
0.37 
60  40ºC/75%RH 141±0.38 118± 0.4 
117± 
0.51 
119± 
0.37 
120± 
0.32 
90  25ºC/60%RH 126±0.28 122± 0.24 
126± 
0.37 
119± 
0.74 
124± 
0.49 
90  30ºC/65%RH 135±0.34 123± 0.25 
123± 
0.51 
117± 
0.25 
118± 
0.25 
90  40ºC/75%RH 141±0.84 119± 0.37
121± 
0.37
119± 
0.27 
120±0.
32 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4
1st   NA 0.218 0.215 0.216 0.482 0.166 
30  25ºC/60%RH 0.158 0.135 0.391 0.258 0.251 
30 30ºC/65%RH 0.068 0.161 0.089 0.139 0.58 
30  40ºC/75%RH 0.125 0.164 0.19 0.076 0.122 
60  25ºC/60%RH 0.054 0.053 0.103 0.093 0.092 
60  30ºC/65%RH 0.152 0.028 0.009 0.098 0.101 
60  40ºC/75%RH 0.067 0.159 0.094 0.096 0.053 
90  25ºC/60%RH 0.215 0.154 0.04 0.017 0.083 
90  30ºC/65%RH 0.158 0.166 0.094 0.098 0.081 
90  40ºC/75%RH 0.216 0.076 0.099 0.091 0.081 
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Table No: 6.5  Disintegration Time (min.) 
   n=6, Mean ± S.D 
 
Table No: 6.6  LOD for Tablets % L 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4
1st  NA 1.89 1.69 1.71 1.57 1.50 
30  25ºC/60%RH 2.15 1.89 1.98 1.98 1.98 
30  30ºC/65%RH 2.36 1.96 2.45 1.96 2.15 
30 40ºC/75%RH 1.89 2.35 2.15 1.64 2.26 
60  25ºC/60%RH 1.58 2.15 2.15 2.18 1.95 
60  30ºC/65%RH 2.06 2.25 2.16 1.96 1.86 
60  40ºC/75%RH 2.25 2.36 2.11 1.65 1.85 
90  25ºC/60%RH 2.12 2.18 1.95 2.16 2.10 
90  30ºC/65%RH 1.98 1.96 2.11 2.18 2.26 
90  40ºC/75%RH 1.65 1.98 2.34 2.17 2.23 
  
Table No: 6.7  Assay for Tablets (%) 
 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4
1st NA 98.65 99.18 100.18 98.10 99.68 
30  25ºC/60%RH 97.05 99.07 98.08 99.07 99.07 
30  30ºC/65%RH 97.26 98.08 99.12 98.12 99.07 
30  40ºC/75%RH 96.23 98.07 99.14 98.22 98.12 
60  25ºC/60%RH 96.52 98.08 97.12 99.12 99.12 
60  30ºC/65%RH 96.32 99.98 98.14 99.72 99.84 
60  40ºC/75%RH 97.23 98.12 98.19 99.14 98.12 
90 25ºC/60%RH 98.12 97.09 98.14 98.12 98.14 
90  30ºC/65%RH 98.12 99.08 99.12 97.14 98.12 
90  40ºC/75%RH 98.21 97.02 98.76 99.18 99.14 
 
DAYS Stability Conditions CONTROL EFT1 EFT2 EFT3 EFT4 
1st  NA 18.06±0.4 5.17±0.5 16.10±0.8 8.02±0.6 7.50±0.8 
30  25ºC/60%RH 18.37±02 5.37±0.3 15.59±0.7 9.13±0.8 7.44±0.6 
30 30ºC/65%RH 19.38±0.1 2.50±0.4 17.48±0.4 8.40±0.2 7.23±0.5 
30  40ºC/75%RH 19.12±0.12 3.49±0.1 17.43±0.2 8.40±0.1 7.52±0.15
60  25ºC/60%RH 17.12±0.14 5.58±0.2 16.43±0.3 10.03±0.2 8.08±0.4 
60  30ºC/65%RH 17.18±0.24 3.18±0.2 17.56±0.1 9.04±0.1 8.17±0.2 
60 40ºC/75%RH 17.56±0.34 3.57±0.2 17.56±0.2 8.54±0.2 7.53±0.1 
90  25ºC/60%RH 18.18±0.24 6.03±0.3 16.57±0.4 10.16±0.5 8.13±0.2 
90  30ºC/65%RH 19.12±0.28 4.04±0.1 17.55±0.3 9.05±0.06 8.56±0.1 
90 40ºC/75%RH 18.12±0.29 4.18±0.3 17.54±0.2 9.04±0.05 9.01±0.2 
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FIG NO: 6.1 COMPARATIVE DISSOLUTION PROFILE OF EFAVIRENZ 
600mg AT 50 rpm IN 1000ml WATER WITH 2% SLS 
(COMPENDIA MEDIUM) ON 1st DAY 
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FIG NO: 6.2 COMPARATIVE DISSOLUTION PROFILE OF EFAVIRENZ 
600mg AT 50 rpm IN 1000 ml WATER WITH 0.2% SLS  
(QUASI SINK MEDIUM) ON 1st DAY 
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FIG NO: 6.16 COMPARATIVE DISSOLUTION PROFILE OF 
EFAVIRENZ 600mg AT 50 rpm IN 1000ml WATER WITH 0.2% SLS 30th DAY 
STABILITY ANALYSIS 
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FIG NO: 6.17 COMPARATIVE DISSOLUTION PROFILE OF 
EFAVIRENZ 600mg AT 50 rpm IN 1000ml WATER WITH 2% SLS 60th DAY  
STABILITY ANALYSIS 
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FIG NO: 6.18 COMPARATIVE DISSOLUTION PROFILE OF  
EFAVIRENZ 600mg AT 50 rpm IN 1000ml WATER WITH 2% SLS 90th DAY  
STABILITY ANALYSIS 
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TABLE NO: 6.22 T50 AND T80 VALUES OF EFAVIRENZ (600mg) TABLETS 
         IN 1000 ml WITH DIFFERENT SLS CONCENTRATION 
 
 
TRIALS 
T50 IN MEDIA WITH DIFFERENT 
SLS CONCENTRATION 
T80 IN MEDIA WITH DIFFERENT 
SLS CONCENTRATION 
1000ml 
2% SLS 
1000ml 
0.2% SLS 
1000ml 
2% SLS 
1000ml  
0.2% SLS 
EFT1 17.47 NA 44.27 NA 
EFT2 27.66 NA NA NA 
EFT3 9.16 NA 34.51 NA 
EFT4 9.62 22.21 27.54 NA 
 
 
 
 
 
 
 
FIG NO: 6.7 COMPARISION OF T50 AND T80 VALUES OF  
EFAVIRENZ (600mg) TABLETS IN 1000 ml WATER WITH 2% SLS 
 (COMPENDIA MEDIUM) 
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FIG NO: 6.8 T50 AND T80 VALUES OF EFAVIRENZ (600mg) TABLETS 
AT 50 rpm IN 1000 ml WATER WITH 0.2% SLS  
(QUASI SINK MEDIUM) 
 
 
TABLE NO: 6.25  T50 AND T80 DATA OF EFAVIRENZ 600mg TABLETS  
STABILITY ANALYSIS  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIALS DAYS 
25ºC-60%RH 30 ºC -65%RH 40 ºC -75%RH 
T50 T80 T50 T80 T50 T80 
EFT1 
30 17.78 45.16 20.64 51.38 20.49 52.19 
60 18.91 49.94 18.28 46.29 17.47 51.32 
90 20.29 46.98 20.11 51.46 20.17 55.80 
EFT2 
30 27.18 NA 29.13 NA 34.01 NA 
60 26.13 NA 35.69 NA 29.00 NA 
90 48.36 NA 28.33 NA 36.85 NA 
EFT3 
30 9.13 32.93 10.44 36.77 10.48 40.69 
60 9.44 39.92 10.08 32.00 10.07 39.06 
90 9.39 43.68 11.17 40.16 11.07 36.75 
EFT4 
30 9.45 30.48 10.19 46.88 9.97 27.73 
60 8.74 40.22 8.81 29.14 9.25 26.02 
90 9.60 33.29 9.93 28.44 9.24 25.44 
                                                                       RESULTS AND DISCUSSION                     
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 59                            
 
 
 
 
 
 
 
  
 
 
 
 
FIG NO: 6.19 T50 AND T80 DATA OF EFAVIRENZ 600mg TABLETS 
30th DAY  STABILITY ANALYSIS 
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FIG NO: 6.20 T50 AND T80 DATA OF EFAVIRENZ 600mg TABLETS 
60th DAY  STABILITY ANALYSIS 
 
 
                                                                       RESULTS AND DISCUSSION                     
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 61                            
 
 
 
 
 
 
 
 
 
 
FIG NO: 6.21 T50 AND T80 DATA OF EFAVIRENZ 600mg TABLETS 90th DAY  
STABILITY ANALYSIS
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FIG NO: 6.13 Dissolution Efficiency (DE 30) of Efavirenz 600mg Tablets 
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For Acyclovir (800mg) 
 
Table No: 6.8   Physical Parameters 
Physical 
Parameters 
Batches 
Control ACT1 ACT2 ACT3 ACT4 
Appearance White, capsule Shaped 
LOD for granules %L 1.64 1.53 1.68 1.72 1.96 
Bulk Density (wt/ml) 0.5522 0.5448 0.5512 0.5461 0.5481
Tapped Density 
(wt/ml) 0.6264 0.6486 0.6312 0.6318 0.6418
%  Compressibility 11.85 16.00 12.67 13.56 14.60 
Assay of granules (%) 98.89 99.18 99.48 101.12 100.78
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Table No: 6.9  Weight Variation (gm) 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4 
1st NA 1.5174± 0.014 
1.5123±
0.009 
1.5083±
0.006 
1.502± 
0.0051 
1.5065± 
0.004 
30 25ºC/60%RH 1.5162± 0.02 
1.5058±
0.002 
1.5092±
0.001 
1.5078± 
0.003 
1.5047± 
0.003 
30  30ºC/65%RH 1.5124± 0.02 
1.5052±
0.004 
1.5043±
0.003 
1.5043± 
0.003 
1.5076± 
0.003 
30  40ºC/75%RH 1.5094± 0.3 
1.5062±
0.004 
1.5042±
0.0025 
1.5062± 
0.003 
1.5031± 
0.002 
60  25ºC/60%RH 1.5082± 0.3 
1.5104±
0.003 
1.5108±
0.003 
1.5106± 
0.002 
1.5118± 
0.004 
60 30ºC/65%RH 1.5034± 0.012 
1.5086±
0.003 
1.5104±
0.004 
1.507± 
0.003 
1.5084± 
0.002 
60 40ºC/75%RH 1.5048± 0.14 
1.5089±
0.003 
1.506± 
0.003 
1.507± 
0.003 
1.5098± 
0.002 
90  25ºC/60%RH 1.5052± 0.24 
1.5114±
0.004 
1.5113±
0.003 
1.508± 
0.0024 
1.5096± 
0.004 
90  30ºC/65%RH 1.5068± 0.3 
1.5086±
0.003 
1.5078±
0.002 
1.5081± 
0.0021 
1.5073± 
0.004 
90 40ºC/75%RH 1.5084± 0.12 
1.5071±
0.0018 
1.5082±
0.0015 
1.5093± 
0.004 
1.5093± 
0.003 
   n=20, Mean ± S.D 
 
Table No: 6.10  Hardness (N) 
      n=10, Mean ± S.D. 
 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4 
1st NA 153±0.3 160±0.3 147±0.2 118±0.5 141±0.5 
30  25ºC/60%RH 161±0.2 145±0.3 141±0.2 113±0.4 139±0.2 
30 30ºC/65%RH 154±0.3 142±0.2 139±0.2 117±0.2 139±0.2 
30  40ºC/75%RH 168±0.3 142±0.4 139±0.2 105±0.3 137±0.4 
60  25ºC/60%RH 158±0.2 150±0.5 144±0.3 126±0.3 136±0.8 
60  30ºC/65%RH 155±0.3 150±0.6 149±0.7 128±0.2 146±0.2 
60  40ºC/75%RH 156±0.3 157±0.5 149±0.2 125±0.5 137±0.5 
90  25ºC/60%RH 161±0.2 150±0.4 151±0.3 131±0.4 138±0.9 
90  30ºC/65%RH 162±0.3 152±0.4 153±0.4 130±0.2 148±0.2 
90  40ºC/75%RH 154±0.3 150±0.3 142±0.4 129±0.2 133±0.8 
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Table No: 6.11  Friability (%) 
 
 
 
 
 
 
Table No: 6.12  Disintegration Time (min) 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4 
1st NA 10.06±0.4 6.15±0.7 9.54±0.8 3.28±0.6 5.24±1.1 
30  25ºC/60%RH 11.06±0.3 9.07±0.2 7.43±0.4 2.5±0.4 5.11±0.2 
30 30ºC/65%RH 12.05±0.1 6.53±0.2 5.4±0.2 2.44±0.3 3.44±0.1 
30 40ºC/75%RH 11.56±0.1 9.16±0.2 8.18±0.3 2.24±0.2 3.47±0.2 
60  25ºC/60%RH 12.10±0.1 10.46±0.3 9.17±0.2 3.18±0.4 5.38±0.2 
60  30ºC/65%RH 11.52±0.2 7.23±0.1 7.35±0.3 3.26±0.5 4.28±0.1 
60 40ºC/75%RH 11.46±0.3 9.24±0.2 8.12±0.2 3.31±0.3 4.35±0.2 
90  25ºC/60%RH 10.56±0.4 10.53±0.2 10.30±0.2 3.39±0.3 6.14±0.2 
90  30ºC/65%RH 10.54±0.3 7.21±0.3 8.18±0.3 3.25±0.2 4.05±0.1 
90  40ºC/75%RH 10.52±0.1 9.28±0.1 8.52±0.1 3.47±0.3 5.30±0.1 
  n=6, Mean ± S. 
 
 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4
1st NA 0.118 0.054 0.119 0.276 0.046 
30  25ºC/60%RH 0.054 0.14 0.13 0.075 0.035 
30  30ºC/65%RH 0.256 0.197 0.133 0.055 0.132 
30 40ºC/75%RH 0.356 0.134 0.009 0.137 0.018 
60  25ºC/60%RH 0.127 0.086 0.09 0.074 0.018 
60  30ºC/65%RH 0.258 0.018 0.24 0.075 0.032 
60  40ºC/75%RH 0.123 0.083 0.081 0.172 0.091 
90  25ºC/60%RH 0.123 0.078 0.039 0.124 0.076 
90  30ºC/65%RH 0.152 0.012 0.072 0.064 0.077 
90  40ºC/75%RH 0.165 0.14 0.09 0.179 0.147 
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Table No: 6.13  LOD for Tablets %L 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4
1st NA 1.59 1.82 1.66 1.99 1.95 
30  25ºC/60%RH 1.98 1.98 1.98 1.98 2.12 
30 30ºC/65%RH 1.97 2.13 1.96 2.15 2.13 
30 40ºC/75%RH 1.85 2.46 1.93 2.36 2.15 
60 25ºC/60%RH 1.59 2.15 2.05 2.45 2.27
60 30ºC/65%RH 1.65 2.16 2.15 2.14 2.29 
60  40ºC/75%RH 1.97 2.33 2.31 2.33 2.14 
90 25ºC/60%RH 1.65 2.15 2.25 2.12 2.31 
90 30ºC/65%RH 1.96 2.45 2.24 2.18 2.12 
90  40ºC/75%RH 1.78 2.44 1.98 1.95 2.04 
 
 
 
 
 
 
 
Table No: 6.14  Assay for Tablets (%) 
DAYS Stability Conditions CONTROL ACT1 ACT2 ACT3 ACT4 
1st NA 98.45 99.55 99.46 100.31 100.31
30  25ºC/60%RH 98.21 101.02 102.78 102.12 99.14 
30  30ºC/65%RH 97.54 99.09 99.14 101.04 98.14 
30  40ºC/75%RH 99.12 99.72 99.17 99.78 100.12
60 25ºC/60%RH 101.12 101.62 101.14 101.26 100.78
60 30ºC/65%RH 99.52 99.78 98.98 99.47 99.37 
60  40ºC/75%RH 98.25 99.98 98.17 99.12 98.96 
90  25ºC/60%RH 98.32 101.78 101.34 101.34 100.34
90  30ºC/65%RH 97.35 99.24 99.64 99.64 98.93 
90 40ºC/75%RH 97.25 99.12 98.97 98.97 99.17 
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FIG NO: 6.3 COMPARATIVE DISSOLUTION PROFILE OF 
ACYCLOVIR 800mg IN 900ml 0.1N HCl 
(COMPENDIA MEDIUM) ON 1st DAY 
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FIG NO: 6.4 COMPARATIVE DISSOLUTION PROFILE OF 
ACYCLOVIR 800mg IN 500 ml 0.1N HCl 
(QUASI SINK) ON 1st DAY 
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FIG NO: 6.22 COMPARATIVE DISSOLUTION PROFILE OF 
ACYCLOVIR 800mg IN 900 ml 0.1N HCl 30th 
DAY STABILITY ANALYSIS 
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FIG NO: 6.23 COMPARATIVE DISSOLUTION PROFILE OF  
ACYCLOVIR 800mg IN 900 ml 0.1N HCl 60th DAY  
STABILITY ANALYSIS 
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                  FIG NO: 6.24 COMPARATIVE DISSOLUTION PROFILE OF  
ACYCLOVIR 800mg IN 900 ml 0.1N HCl 90th DAY  
STABILITY ANALYSIS 
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 TABLE NO: 6.23  T50 AND T80 VALUES OF ACYCLOVIR (800mg) TABLETS 
AT 50 rpm WITH 0.1N HCl 
 
TRIALS 
T50 IN 0.1N HCl T80 IN 0.1N HCl 
900ml 
(COMPENDIA) 
500ml 
(QUASI SINK) 
900ml 
(COMPENDIA) 
500ml 
(QUASI SINK) 
ACT1 0.87 1.23 32.81 41.51 
ACT2 0.08 0.77 5.70 11.08 
ACT3 0.93 2.36 9.74 47.13 
ACT4 2.99 3.01 5.56 9.08 
 
 
 
 
 
 
FIG NO: 6.9 COMPARATIVE T50 AND T80 DATA OF ACYCLOVIR 800mg 
TABLETS AT 50 rpm IN 900 ml 0.1N HCl 
(COMPENDIA MEDIUM) 
 
                                                                       RESULTS AND DISCUSSION                          
 
R.V.S. College of Pharmaceutical Sciences,Coimbatore                                       Page 72                                   
 
   
 
 
 
 
 
 
 
 
 
 FIG NO: 6.10 COMPARATIVE T50 AND T80 DATA OF ACYCLOVIR 800mg                  
                                  TABLET    AT 50 rpm IN 500 ml 0.1N HCl 
                                                 (QUASI SINK MEDIUM) 
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    TABLE NO: 6.26  T 50 AND T80 DATA OF ACYCLOVIR 800mg TABLETS 
                                                    STABILITY ANALYSIS 
 
                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIALS DAYS
25ºC-60%RH 30ºC -65%RH 40ºC -75%RH 
T50 T80 T50 T80 T50 T80 
ACT1 
30 1.14 5.88 3.82 10.72 1.34 6.21 
60 2.27 7.31 3.11 6.49 0.14 5.04 
90 2.42 13.12 3.43 15.76 3.21 8.58 
ACT2 
30 3.29 6.79 3.19 7.77 4.70 6.89 
60 3.29 6.83 4.19 6.70 3.79 8.69 
90 2.35 5.15 2.66 7.30 2.29 9.21 
ACT3 
30 2.77 8.34 2.35 6.02 1.26 5.05 
60 1.96 19.81 0.63 5.49 0.11 15.80 
90 2.52 6.85 2.73 12.10 1.29 12.95 
ACT4 
30 4.09 9.73 6.42 22.26 4.47 8.88 
60 3.65 15.56 2.37 7.61 1.23 8.90 
90 1.42 8.15 2.02 8.38 2.02 8.38 
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FIG NO: 6.25 COMPARATIVE T 50 AND T80 DATA OF ACYCLOVIR 800mg 
30th DAY STABILITY ANALYSIS 
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FIG NO: 6.26 COMPARATIVE T 50 AND T80 DATA OF ACYCLOVIR 800mg  
60th DAY  STABILITY ANALYSIS 
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FIG NO: 6.27 COMPARATIVE T 50 AND T80 DATA OF ACYCLOVIR 800mg  
90th DAY  STABILITY ANALYSIS
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FIG NO: 6.14 Dissolution Efficiency (DE 30) of Acyclovir 800mg Tablets 
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For Nevirapine (200mg) 
Table No: 6.15  Physical Parameters 
Physical 
Parameters 
Batches 
Control NET1 NET2 NET3 NET4 
Appearance White, capsule Shaped 
LOD for granules %L 1.64 1.68 1.72 1.86 1.89 
Bulk Density (wt/ml) 0.4542 0.432 0.418 0.436 0.438 
Tapped Density (wt/ml) 0.5164 0.5273 0.5185 0.5215 0.5286 
% Compressibility 12.04 18.07 19.38 16.4 17.14 
Assay of granules (%) 98.89 99.8 100.8 100.6 101.8 
 
 
Table No: 6.16  Weight Variation (gm) 
 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 0.854± 0.024 
0.852± 
0.001 
0.852± 
0.0014 
0.853± 
0.0016 
0.854± 
0.0026 
30 25ºC/60%RH 0.8532± 0.02 
0.8530
± 
0.002 
0.8532
± 
0.001 
0.8525
± 
0.002 
0.8527
± 
0.01 
30 30ºC/65%RH 0.8584± 0.02 
0.8524
± 
0.002 
0.8515
± 
0.001 
0.8520
± 
0.002 
0.8527
± 
0.0007 
30 40ºC/75%RH 0.8592± 0.001 
0.8522
± 
0.002 
0.8534
± 
0.002 
0.8527
± 
0.0009 
0.8521
± 
0.001 
60 25ºC/60%RH 0.8564± 0.02 
0.8532
± 
0.002 
0.8544
± 
0.002 
0.8534
± 
0.002 
0.854± 
0.002 
60 30ºC/65%RH 0.8532± 0.01 
0.8535
± 
0.002 
0.8541
± 
0.002 
0.8526
± 
0.002 
0.8502
± 
0.002 
60 40ºC/75%RH 0.8564± 0.002 
0.8534
± 
0.003 
0.8527
± 
0.002 
0.8525
± 
0.0012 
0.853± 
0.002 
90 25ºC/60%RH 0.8512± 0.001 
0.8542
± 
0.002 
0.8544
± 
0.002 
0.8541
± 
0.002 
0.8543
± 
0.002 
90 30ºC/65%RH 0.8524± 0.01 
0.854± 
0.002 
0.8534
± 
0.002 
0.8533
± 
0.002 
0.8537
± 
0.0012 
90 40ºC/75%RH 0.8562± 0.02 
0.8531
± 
0.002 
0.8527
± 
0.001 
0.8525
± 
0.002 
0.8530
± 
0.0016 
n=20, Mean ± S.D 
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Table No: 6.17  Hardness (N) 
 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 103±0.35 103.4± 0.346 
104.2± 
0.245 
106.4± 
0.562 
103.6± 
0.456 
30 25ºC/60%RH 105±0.02 96± 0.374 
104± 
0.374 
96± 
0.374 
108± 
0.51 
30 30ºC/65%RH 108±0.012 102± 0.25 
90± 
0.32 
93± 
0.51 
97± 
0.25 
30 40ºC/75%RH 110±0.03 102± 0.24 
98± 
0.25 
94± 
0.37 
97± 
0.35 
60 25ºC/60%RH 114±0.02 103± 0.258 
107± 
0.5 
104± 
0.65 
110± 
0.56 
60 30ºC/65%RH 115±0.01 108± 0.28 
98± 
0.48 
98± 
0.51 
113± 
0.19 
60 40ºC/75%RH 116±0.02 111± 0.37 
101± 
0.4 
103± 
0.54 
108± 
0.4 
90 25ºC/60%RH 108±0.01 111± 0.47 
106± 
0.64 
108± 
0.47 
110± 
0.48 
90 30ºC/65%RH 110±0.03 112± 0.43 
105± 
0.61 
103± 
0.8 
110± 
0.39 
90 40ºC/75%RH 108±0.02 111± 0.58 
107.2± 
0.19 
104± 
0.55 
111± 
0.47 
n=10, Mean ± S.D 
 
 
Table No: 6.18  Friability (%) 
 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 0.018 0.023 0.105 0.099 0.098 
30 25ºC/60%RH 0.018 0.049 0.004 0.046 0.026 
30 30ºC/65%RH 0.156 0.054 0.042 0.113 0.087 
30 40ºC/75%RH 0.025 0.09 0.016 0.131 0.094 
60 25ºC/60%RH 0.065 0.04 0.016 0.136 0.112 
60 30ºC/65%RH 0.098 0.133 0.117 0.068 0.103 
60 40ºC/75%RH 0.152 0.148 0.12 0.105 0.021 
90 25ºC/60%RH 0.012 0.098 0.213 0.225 0.17 
90 30ºC/65%RH 0.132 0.061 0.193 0.035 0.131 
90 40ºC/75%RH 0.015 0.115 0.024 0.134 0.134 
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Table No: 6.19  Disintegration Time (min) 
 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 3.06±0.4 2.0±0.06 0.46±0.08 0.10±0.05 0.09±0.01 
30  25ºC/60%RH 4.10±0.1 1.01±0.1 0.45±0.2 0.10±0.1 0.09±0.2 
30  30ºC/65%RH 4.12±0.25 0.58±0.2 1.03±0.1 0.09±0.2 0.13±0.1 
30 40ºC/75%RH 3.55±0.26 1.07±0.1 0.57±0.2 0.09±0.1 0.09±0.2 
60 25ºC/60%RH 4.01±0.36 1.28±0.1 0.49±0.2 0.12±0.2 0.09±0.1 
60  30ºC/65%RH 3.18±0.12 1.18±0.1 1.05±0.3 0.11±0.1 0.14±0.2 
60  40ºC/75%RH 3.25±0.2 1.18±0.1 1.04±0.1 0.10±0.2 0.09±0.1 
90  25ºC/60%RH 3.48±0.21 1.17±0.2 0.49±0.3 0.11±0.2 0.12±0.2 
90  30ºC/65%RH 3.52±0.32 1.07±0.4 1.09±0.4 0.10±0.1 0.14±0.1 
90 40ºC/75%RH 3.42±0.12 1.13±0.1 0.59±0.1 0.10±0.2 0.10±0.2 
   n=6, Mean ± S.D 
 
Table No: 6.20  LOD for Tablets %L 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 1.97 1.98 1.78 1.98 1.99 
30  25ºC/60%RH 1.96 1.69 1.89 2.15 2.11 
30  30ºC/65%RH 2.15 1.65 2.15 1.93 1.69 
30 40ºC/75%RH 2.16 2.11 2.16 2.15 1.65 
60  25ºC/60%RH 2.11 2.15 2.15 1.69 2.13 
60  30ºC/65%RH 2.08 1.96 1.97 1.68 1.96 
60 40ºC/75%RH 1.96 2.15 2.10 1.88 1.86 
90  25ºC/60%RH 1.69 1.65 2.10 2.14 2.13 
90  30ºC/65%RH 1.65 1.98 1.87 2.15 1.96 
90  40ºC/75%RH 1.98 1.99 2.20 2.46 1.98 
   
 
Table No: 6.21  Assay for Tablets (%) 
DAYS Stability Conditions CONTROL NET1 NET2 NET3 NET4 
1st NA 98.4 99.4 99.8 98.9 101.3 
30  25ºC/60%RH 99.45 98.17 99.14 100.12 99.12 
30  30ºC/65%RH 99.87 99.14 98.78 99.86 99.14 
30  40ºC/75%RH 98.15 99.12 99.19 99.76 99.78 
60 25ºC/60%RH 96.56 98.12 99.12 100.13 100.26
60  30ºC/65%RH 97.89 99.14 99.78 99.14 99.34 
60  40ºC/75%RH 98.63 98.12 98.16 99.26 99.56 
90  25ºC/60%RH 96.32 100.12 99.74 100.76 101.10
90  30ºC/65%RH 98.65 99.78 99.17 100.12 102.12
90 40ºC/75%RH 97.56 99.14 98.94 100.14 101.08
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FIG NO: 6.5 COMPARATIVE DISSOLUTION PROFILE OF NEVIRAPINE 
200mg AT 50 rpm IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER 
(COMPENDIA MEDIUM) ON 1st DAY 
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FIG NO: 6.6 COMPARATIVE DISSOLUTION PROFILE OF NEVIRAPINE 
200mg AT 50 rpm IN 500 ml 0.1M pH 2 PHOSPHATE BUFFER  
(QUASI SINK MEDIUM) ON 1st DAY 
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FIG NO: 6.28 COMPARATIVE DISSOLUTION PROFILE OF NEVIRAPINE 
200mg IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER  30th DAY 
STABILITY ANALYSIS 
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FIG NO: 6.29 COMPARATIVE DISSOLUTION PROFILE OF NEVIRAPINE       
200mg IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER 60th DAY  
STABILITY ANALYSIS 
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FIG NO: 6.30 COMPARATIVE DISSOLUTION PROFILE OF NEVIRAPINE 
200mg IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER 90th DAY  
STABILITY ANALYSIS 
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TABLE NO: 6.24 T50 AND T80 VALUES OF NEVIRAPINE (200mg) TABLETS 
AT 50 rpm WITH pH 2.0 PHOSPHATE BUFFER 
 
 
TRIALS 
T50 IN pH 2.0 PHOSPHATE 
BUFFER T80 IN pH 2.0 PHOSPHATE BUFFER 
900ml 
(COMPENDIA) 
500ml 
(QUASI SINK) 
900ml 
(COMPENDIA) 
500ml 
(QUASI SINK) 
NET1 5.77 6.14 15.67 35.6 
NET2 4.49 5.20 14.17 27.92 
NET3 4.41 7.08 10.0 36.79 
NET4 3.47 7.08 7.66 16.53 
 
 
 
 
 
 
FIG NO: 6.11 T50 AND T80VALUES OF NEVIRAPINE 200mg TABLETS  
AT 50 rpm IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER  
(COMPENDIA MEDIUM) 
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FIG NO: 6.12 T50 AND T80VALUES OF NEVIRAPINE 200mg TABLETS 
AT 50 rpm IN 900 ml 0.1M pH 2 PHOSPHATE BUFFER 
(QUASI SINK MEDIUM) 
 
 
TABLE NO: 6.27  T50 AND T80 DATA OF NEVIRAPINE 200mg TABLETS   
STABILITY ANALYSIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRIALS DAYS
25ºC-60%RH 30ºC -65%RH 40ºC -75%RH 
T50 T80 T50 T80 T50 T80 
NET1 
30 4.91 11.43 5.21 15.11 4.86 14.63 
60 5.05 13.05 6.09 20.05 5.92 14.24 
90 4.91 9.91 4.87 14.46 6.26 12.65 
NET2 
30 4.61 10.78 4.82 14.72 4.37 10.30 
60 4.48 12.99 5.41 12.21 5.80 16.99 
90 2.74 8.17 4.19 12.18 4.50 10.45 
NET3 
30 4.04 11.32 5.11 15.85 4.35 14.19 
60 5.08 18.28 4.12 11.71 4.53 14.28 
90 4.88 12.70 5.34 11.81 4.97 4.18 
NET4 
30 4.33 10.29 4.95 12.83 4.37 9.36 
60 4.98 12.48 4.09 11.82 4.88 10.66 
90 5.43 14.65 4.84 10.81 4.18 8.38 
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FIG NO: 6.31 COMPARATIVE T50 AND T80 DATA OF NEVIRAPINE 200mg 
TABLETS ON 30th DAY  STABILITY ANALYSIS 
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FIG NO: 6.32 COMPARATIVE T50 AND T80 DATA OF NEVIRAPINE 200mg  
TABLETS ON 60th DAY  STABILITY ANALYSIS 
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FIG NO: 6.33 COMPARATIVE T50 AND T80 DATA OF NEVIRAPINE 200mg  
TABLETS ON 90th DAY  STABILITY ANALYSIS 
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FIG NO: 6.15 Dissolution Efficiency (DE 30) of Nevirapine 200mg Tablets 
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7. CONCLUSION 
All the drugs were selected for this study do not have adequate aqueous 
solubility and  are in high  dose  drugs. In the  disintegration  test Polyplasdone XL10 
crospovidone showed a better result than other superdisintegrants used in these 
studies. 
 In the in vitro drug release study, (Compendia  medium  and  Quasi-sink 
medium) Polyplasdone XL10  crospovidone   showed  faster release when compared  
with other  superdisintegrants  used  in this study. 
 From the result of DE30, Polyplasdone XL10 crospovidone having higher DE30  
compared with other superdisintegrants used in this study. 
 In the stability study revealed that the developed formulations were stable in 
three different temperatures and humidity conditions for the period of three months 
according to ICH Guidelines. 
 This study demonstrated the effectiveness of Polyplasdone XL10 
crospovidone as a superdisintegrant for these three poorly soluble drugs, and as 
Polyplasdone XL10 crospovidone recommended as a good disintegrant in tablet 
formulations of these poorly soluble drugs. 
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